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Abstract 
Background: Management of a transplant recipient involves the use of multiple 
immunosuppressant drugs. Currently there is no test that reflects the overall immune 
status of the patient. This results in under or over suppression of the immune system and 
consequently increases in morbidity and mortality rates. Evaluation of the proliferative 
response of PBMC's to a mitogen PHA by measurement of intracellular ATP was 
evaluated as a tool to assess the immune response in kidney transplant patients. 
Method: PBMC's were separated from the blood samples of healthy controls and kidney 
transplant patients on cyclosporine, sirolimus, and tacrolimus based regimens by density 
gradient centrifugation, cells were counted and incubated overnight with and without 
PHA. The luciferin-Iuciferase enzyme reaction which induces bioluminescence and the 
Turner Biosystem luminometer were used to measure intracellular ATP levels in relative 
light units (RLU). An A TP standard curve was generated for each test. 
Results: The ATP (nglml) levels measured in the transplant recipients were lower and 
statistically significantly different (p< 0.0001) than the healthy controls. No statistically 
significant difference was measured between the cycIosporine and sirolimus drug groups. 
Patients on tacrolimus gave a statistically significant (p<O.0001) stronger immune 
response than those receiving cyclosporine and sirolimus. Overall, the immune response 
results of kidney transplant patients were statistically significantly lower than the healthy 
control by 981 nglml. Linear regression analysis revealed no correlation between patient 
A TP (nglml) levels and therapeutic drug blood levels, immunosuppressant drug dosages, 
creatinine levels and white cell counts. The immune responses of patients who were 
xv 
diagnosed with infection or were clinically stable were characterised as low or moderate, 
of interest, one patient who was diagnosed with rejection was found to have a strong 
immune response (>501 nglml ATP). 
Conclusion: Future studies to determine the predictive value of the A TP assay in 
directing immunosuppressive therapy are required. The assay described in this study is 
simple, sensitive and rapid and has possible application in immunological monitoring in a 
variety of conditions that affects the immune system. 
Keywords: kidney transplantation, immunosuppression, bioluminescence, lymphocyte, 




A fully responsive immune system is essential for combating harmful agents in the body 
however in some instances this is undesirable for example an immunological response to 
a transplanted organ. The common approach for preventing or controlling immune 
reactions in transplant recipients is to administer immunosuppressive drugs. (Rowley et 
aI., 1973) 
Even though most of the technical problems of renal transplantation have been solved 
and despite the improvements in immunosuppressant protocols the variety of drug related 
complications i.e. opportunistic infections, malignancies, acute/chronic rejection and drug 
toxicities are still major causes of morbidity and mortality. (Truong et aI., 2007., Sayegh 
and Carpenter, 2004) Studies have shown that early detection of these complications will 
result in improved graft survival and improve the recipients' quality of life. (Chavez et 
aI., 2006., Penn and Starzl, 1972) 
The complications mentioned above may be directly or indirectly related to the lack of an 
immunological test to assess the interaction between the immune suppressant drugs and 
the transplant recipients' immune system. (Truong et aI., 2007) Thus to prevent these 
complications a tool is needed to monitor the changes in the immune system which will 
help manage immunosuppression therapy. A study by Shulick et aI., (1993) highlighted 
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the importance of monitoring the immune system as a way to optimise immuno-
suppressive therapy. (Schulick et aI., 1993) 
Lymphocytes, playa major role in the immune response against transplanted organs, 
hence most immunosuppressive therapy targets these cells. When these cells are 
undergoing suppression or death the levels of A TP which provides energy to the cells is 
significantly decreased like wise when cells are activated to proliferate there is a rapid 
increase in the levels of A TP hence A TP may be use as a biological marker to determine 
the viability of lymphocytes. (Crouch et aI., 1993) Firefly bioluminescence which 
involves luciferin and luciferase enzyme reaction requires A TP as a co-factor to produce 
light. (Nakamura et aI., 2006) 
Hence an assay which involves A TP and bioluminescence was investigated as a potential 




1.1 Historical overview 
A half century has elapsed since the first organ transplantation. (Sayegh and Carpenter, 
2004) In the early 1950's, there was a growing certainty that immunological mechanisms 
were involved in the destruction of transplanted kidney. Sir Peter Medawar identified the 
immunologic nature of skin allograft rejection in humans. These findings were based on 
extensive data from animal experimentation. (Medawar et aI., 1953., Medawar, 1944) 
Jean Dausset established that the major histocompatibility complex (MHC) genes are the 
most important markers of an individuals' biological identity and consequently playa 
vital role in transplantation immunology. Ralph Zinkemagel, Peter Gorer and Peter 
Doherty added to the growing pool of immunological knowledge. Peter Gorer established 
that the most important histocompatibility locus was anti gene II, and named the locus 
histocompatibility II. Ralph Zinkemagel and Peter Doherty identified the role of MHC to 
signal foreign antigens to the immune system. (Sharma and Unruh, 2006) 
These discoveries as well as findings in vascular surgical techniques (Murray, 1992) led 
to the first successful kidney transplantation. In 1954, Joseph Murray, John Merrill and 
Hartwell Harrison carried out the first transplantation between identical twins at the Peter 
Bent Brigham Hospital in Boston. The success was attributed to the lack of a rejection 
response. (Murray et aI., 1955., Murray et aI., 1956) 
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However, there still remained the problem of rejection of any kidney other than an 
identical twin' s kidney, this marked the beginning of the evaluation of rejection and 
mechanisms to avoid it. Initial attempts at controlling rejection began with experiments 
involving total body irradiation. However these attempts resulted in poor outcomes. 
(Morris, 1970., Sayegh and Carpenter, 2004., Sharma and Unruh, 2006) 
In the early 1960s, immunosuppression with 6 - mercaptopurine was first used to enable 
transplantation between non identical individuals. It was soon replaced by azathioprine 
which was less toxic. (Morris, 2004) Thomas E. Starzl in the early 1960's, established 
that a combination of corticosteroids and azathioprine led to much better outcome thus 
this combination was predominantly used for the next decade. (Sharma and Unruh, 2006) 
The Swiss biochemist lean-Francis Borel discovered cyclosporine in 1972. (Sharma and 
Unruh, 2006) The first clinical trials for cyclosporine were developed in the late 1980s. 
At the time success of renal transplantation was relatively poor thus the dramatic effect 
cyclosporine had on patient and graft survival was easily recognised. (Morris, 2004) 
However the setback of cyclosporine was its ability to cause acute and chronic 
nephrotoxicity. (Watson et aI., 2005) In 1985 the first monoclonal antibody was 
introduced to treat acute rejection episodes however the toxicity restricted its use. 
(Morris, 2004) 
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Major developments that occurred in the 1990s included the introduction of an alternative 
to cyclosporine, tracrolimus, which was previously predominantly used in liver 
transplantation and mycophenolate mofetil (MMF), was found to be a more effective 
adjunctive agent than azathioprine. The monoclonal antibodies basiliximab and 
daclizumab which target the interleukin-2 receptor (CD25) were approved in 1998 
because of their ability to reduce the risk of acute rejection. (Moore, 2000) In 1999 
sirolimus was added to the list of immunosuppressive drugs. (Danovitch, 2001) 
These findings and others have led to organ transplantation progressing from impossible 
to routine. However there are many challenges yet to overcome; of interest is to explore 
and improve on the powerful tools of biomedical technology currently available. 
(Murray, 1992) 
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1.2 Renal Transplantation 
A diagnosis of end-stage renal disease (ESRD) is made when the kidney becomes 
permanently unable to cleanse the body of harmful substances. Consequently, death from 
the accumulation of waste in the body is imminent unless the person is placed on dialysis 
which is the replacement of the kidneys' excretionary role by artificial means or the 
patient receives a transplant. (Cianci et aI., 1981., Ruth et aI., 1987) 
Kidney transplantation is the treatment of choice for patients with ESRD. (Soulillou, 
2001) A successful kidney transplant improves the quality of life of such patients. 
(Andres, 2005., Bushell and Wood, 1999) Modem medicine has triumphed over many 
challenges to achieve successful organ transplantation. (Howard et aI., 2002) and it has 
become a routine surgical practice. (Lechler et aI., 2005) Renal allograft loss due to 
technical failure which historically was a major challenge is at present extremely rare. 
(Kaplan et aI., 2003., Kaplan and Meier-Kriesche, 2004) 
The diseases that most often associated with chronic renal failure are glomerulonephritis, 
diabetic nephropathy, chronic pyelonephritis, hypertension and polycystic kidney disease. 
(Cianci et aI., 1981) Transplanted kidneys are implanted in the right or left iliac fossa. 
The renal artery is sutured to the internal or external iliac artery and the renal vein to the 
external iliac vein and the ureter is implanted in the bladder wall. (O'Callaghan and 
Brenner, 2000) 
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Approximately 55 000 organ transplants are performed worldwide each year and the 
estimated number of living organ recipients is in the region of 300 000. (Kowalski et aI., 
2003) Approximately 229 kidney transplants are performed each year in South Africa 
with just about five new transplants done per year at the Inkosi Albert Luthuli central 
hospital (IALCH) in KwaZulu-Natai. (Odf, June 2008) 
There are many factors that contribute to the current success following renal 
transplantation which include better methods for preservation of the organs, the 
development of more improved immunosuppressive agents, better understanding of the 
rejection process (Suthanthiran and Strom, 1994) and improvement in surgical 
techniques. (Lechler et aI., 2005) 
Success is however limited by the restricted availability of donor organs, poor long term 
graft survival rates (> 5 years), developing methods to induce transplant tolerance and 
eliminating the need for continuous immunosuppression are the major challenges at 
present. (Lechler et aI., 2005) The immunosuppressive drug regimens currently available 
have significantly improved short term graft survival, in most medical centers one year 
graft survival now has a success rate of 80 - 90% but the same cannot be said about long 
term graft survival. (Hariharan et aI., 2000., Sayegh et aI., 1999) 
The most common cause of late graft loss is premature death of the recipient. Infections, 
stroke, cardiac disease and cancers are among the causes of death in transplant patients 
with transplanted organs that are still functional. (Ojo et aI., 2000., Howard et aI., 2002) 
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1.3 Transplantation Immunology 
When an organ, such as a kidney, is transplanted from a donor into the recipient, the 
immune system of the recipient triggers a response against the new organ as it would to 
any foreign material, setting off a chain of events that can damage the transplanted organ. 
(Wood, 2006) 
The human acquired/specific immunity consists of two distinct yet interactive types of 
immunity, humoral immunity and cell-mediated immunity (CMI). Humoral immunity is 
mediated by B lymphocytes and their production of antibodies, while CMI is mediated by 
T lymphocytes and their interactions with other immune cells. (Roitt, 1991) The actual 
recognition of transplantation antigens is predominantly by T lymphocytes and is referred 
to as allorecognition. (Aw, 2003) 
Two distinct pathways of allorecognition have been described. The direct pathway 
involves receptors on the recipients T cells that directly recognise intact MHC on the 
cells of the transplanted organ. The T cell receptor (TCR) recognises unknown peptides 
bound in the groove of allogeneic MHC molecule. (Liu et aI., 1993) This is thought to be 
due to molecular mimicry, the allogeneic MHC resembles selfMHC. (Sayegh and Turka, 
1998) The indirect pathway requires an antigen presenting cell that intemalises the 
foreign MHC, processes and presents it to a particular subset ofT cells via the recipients' 
MHC molecule. (Briscoe and Sayegh, 2002) 
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1.3.1 The Major histocompatibility complex 
The Major histocompatibility complex (MHC) is the most significant genetic determinant 
of graft acceptance or rejection between genetically distinct individuals. In humans the 
MHC are referred to as Human Leukocyte antigen (HLA). The most intensively studied 
segment of the human genome, the Major histocompatibility complex occupies 4-6 
megabases on the short arm of chromosome 6. HLA molecules are highly polymorphic. 
(Buckley, 2003., Germain, 1994) 
The key role of the HLA molecules is to act as receptors which bind peptide fragments 
of foreign antigens and display it on the cell surface where they can be recognised by T 
cells. (Sayegh and Turka, 1998) The MHC genes, inherited in a classic mendelian 
fashion, have been divided into class I, class II and class ill. (McCluskey and Peh, 1999., 
Buckley, 2003) 
The class I HLA (HLA-A, HLA-B, and HLA-C) are found on virtually all nucleated cell 
surfaces. (Buckley, 2003) Peptides bound by class I HLA molecules are mostly derived 
from endogenous proteins and are recognised by cytotoxic CD8 T cells. (A w, 2003) 
In contrast, the class II HLA (HLA-DR, HLA-DP, and HLA-DQ) are usually only found 
on antigen presenting cells (APC) such as B lymphocytes, macrophages, dendritic cells, 
epithelial cells and monocytes. (Buckley, 2003) The HLA class II molecules are believed 
to play the predominant role in the initial immune response to foreign transplantation 
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antigens. Peptides bound to class II molecules are derived from proteolysis in acidic 
endosomal compartments and represent endocytosed proteins and are recognised by 
helper CD4 T cells. (Sayegh and Turka, 1998) 
Class I HLA molecules consist of two polypeptide chains, a single heavy chain 
complexed to a smaller molecule known as ~2 microglobulin (~2m) which are in a non-
covalent association on the cell surfaces. The heavy chain is inserted into the plasma 
membrane and contains the antigenic portions. There are three domains of the class I 
heavy chain, formed in part by disulfide bonding to make loops (a), a2, (3). The amino 
acid sequence variable regions are on the first and second domains (a\, (2). (Buckley, 





Fig 1.1: Schematic representation ofHLA class I molecule 
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The overall protein structure of the class II molecules is similar to that of HLA class 1. 
Class II HLA molecules consist of two membrane inserted, non-covalently associated 
glycosylated polypeptides called a. and ~ chains. Each of these chains has two domains 
and again the polymorphic regions are mostly on the outer amino terminal, which is the 





Fig 1.2: Schematic representation ofHLA class II molecule 
For reasons that are yet unknown foreign MHC molecules stimulate a much higher 
number of T cells (IO-IOO-fold) than foreign antigen presented by self MHC hence the 
immune response against foreign MHC transplantation antigens are much stronger. 
(Wood, 2006) This makes matching of HLA between donor and recipients very 
important. It has been found that it is essential to match for the HLA A, B and DR 
antigens. (Rose and Hutchinson, 2006) 
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1.3.2 T lymphocyte alloantigen recognition 
T lymphocytes recognition of alloantigens on antigen presenting cells (APC) is the key 
event that initiates allograft rejection. (Buckley, 2003) 
T lymphocytes playa pivotal role in immune responses, they influence a majority of the 
cells in the immune system. The major functions include inducing B cells to produce 
antibody, recruit and activate mononuclear phagocytes and specialised cytotoxic T cells, 
secrete cytokines responsible for growth and differentiation of a range of cell types 
including macrophages and eosinophils. It also plays a role in the regulation of immune 
reactions. (Peakman and Vergani, 1997) 
The T cell receptor (TCR) provides the specificity for an individual's T cell to recognise 
a particular non-self antigen. The TCR has to recognise the foreign antigen in 
combination with a polymorphic MHC molecule. This discriminating co-recognition 
event means that T cells are highly specific and genetically restricted to recognising HLA 
molecules of the individual from which they were derived. This concept is known as 
MHC restriction. The association between the antigen peptide and the T cell receptor is 
known as the T cell antigen recognition complex. (Roitt, 1991., Peakman and Vergani, 
1997) 
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The TCR exists as a heterodimer of which there are two types the a~TCR and yoTCR. 
The a~TCR has been studied the most in humans and has been found to be present in 
90% of peripheral T cells thus much more is known about the responsiveness of a~TCR. 
(peakman and Vergani, 1997) 
Each receptor consists of 2 different polypeptide chains termed the a and ~ chains bound 
by a disulfide bond. The T cell receptor is monovalent and is never secreted. Both chains 
of the TCR have a variable (V) region and a constant (C) region and a short hinge region 
with a cysteine residue that forms the inter-chain disulfide bond. Each chain spans the 
membrane by a hydrophobic transmembrane domain and ends in a short cytoplasmic 
domain. (Peakman and Vergani, 1997) (Refer to Figure 1.3) 
Membrane 
Cytoplasm 
Fig 1.3: Schematic representation of the T cell receptor 
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On the T cell together with the expression ofTCR a complex of molecules termed CD3 is 
also expressed, which are involved in transduction of an activation signal in the TCR. 
(peakman M and Vergani D., 1997) T cells express either CD4 or CD8 glycoproteins on 
their cell surface. Helper CD4 T cells are considered to playa significant role in graft 
rejection. They are responsible for the production of the cytokines that stimulate an 
immune response against the graft. Cytotoxic CD8 T cells produce small amounts of 
cytokines thus their main contribution to graft rejection is through direct lysis of the 
donor cells. (Sayegh and Turka, 1998) 
1.3.3 T lymphocyte activation 
The binding of the TCR to the antigen MHC complex is insufficient to activate T cells 
thus the interaction between T lymphocytes and APC's involves binding of multiple T 
cell surface molecules and their counter receptors. These proteins on the T cell surface 
and on the surface of the APC act as costimulatory signals. (Lechler et aI., 2005) 
The initial signal of activation is provided by the TCR and the MHC peptide antigen 
complex which is stabilised by CD4 or CD8. The TCR signal is transduced via the CD3 
complex. (peakman and Vergani, 1997) 
The costimulatory signal required for T-cell activation, is provided by the interaction 
between B7 on the APC and CD28/CTLA4 on the T cell surface which is the best 
characterised costimulatory molecules. (Suthanthiran and Strom, 1994) This interaction 
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bound intracellular stores and the subsequent activation of a calmodulin-dependent 
phosphatase called calcineurin while diacylglycerol in the presence of increased cytosolic 
free calcium binds to and activates protein kinase C a serine-threonine kinase protein that 
is sensitive to calcium and phospholipids. (Suthanthiran and Strom, 1994., Liu et aI., 
1998) 
Calcineurin dephosphorylates the cytosolic inactive form of the nuclear factor of 
activated T cells termed ''NF -AT". After dephosphorylation, NF -A T is translocated from 
the cytosol to the nucleus where it forms a complex with other DNA binding proteins, 
including fos and jun. The complex of DNA binding proteins, regulate gene transcription 
including the IL-2 gene which results in the growth and proliferation of the T-cell. This is 
an important target of immunosuppressant drugs which act on calcineurin, inhibiting the 
phosphatase activity. (peakman and Vergani, 1997) 
Production of the cytokine interleukin-2 (IL-2) through the signaling pathways, results in 
the IL2 receptors being inserted on their T cell surface which binds with IL2 in an initial 
step towards rapid proliferation ofT cells with the best fit for the presented antigen. (Aw, 
2003., Sayegh et aI., 1999) (Refer to Figure 1.5) 
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Fig 1.5: Schematic representation ofT cell intracellular signaling 
The cytokine IL-2 also plays a role in inducing naive or resting T helper cells to 
differentiate into one of two subclasses, T helper 1 (TH1) cells that assist the cellular or T 
cell response and T helper 2 (TH2) cells that assist the humoral or B cell response. This 
differentiation is driven by a process that is poorly understood however it is suggested 
that it depends on the different cytokines produced. (Peakman and Vergani, 1997., Roitt, 
1991) 
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The THI subset secretes cytokines e.g. Interferon gamma (IFNy) that facilitates a 
pro inflammatory response, promotes the delayed type hypersensitivity reactions (DTHR), 
expansion of cytotoxic T lymphocytes and assists macrophages and natural killer cells to 
develop cytotoxicity against the graft. IFNy also induces and intensifies class I and II 
MHC antigen expression of the graft. (peakman and Vergani, 1997) 
In contrast TH2 cells stimulate B lymphocytes to produce antibodies against the allografts 
functional cells. (Dallman, 1995) TH2 cells produce inhibitory products such as IL 4, IL 
5, IL 6 and IL 10 which counter the effector activity ofThl derived cytokines. (peakman 
and Vergani, 1997) 
The final outcome of cytokine production is the presence of antigen specific, graft 
infiltrating and destructive T cells. These interactions make the rejection of the 
transplanted tissue more efficient. (Suthanthiran and Strom, 1994) 
In the absence of costimulatory signals T cells become unresponsive, fail to secrete 
cytokines and may undergo apoptosis. (Aw, 2003., Sayegh et aI., 1999) Thus T cell 
accessory proteins and their ligands on the APC are targets for anti rejection therapy. 
(Buckley, 2003) 
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1.4 Immunosuppressive Drugs 
The basic immunosuppressive regimen involves the use of mUltiple drugs each directed at 
a distinct site in the cascade of T cell activation, cytokine production and clonal 
expansion. Commonly transplant centers use regimens that have been developed 
according to the local response to the drugs. (Danovitch, 200 I) 
The factors that are taken into consideration when choosing the most favourable 
immunosuppressive regimen include whether it is a ftrst or subsequent transplant, 
cadaver versus living related transplant, previous pregnancy, patients biological age, 
weight, ethnicity, the medical history of the patient and the degree ofHLA matching. The 
risk of acute rejection is highest in the ftrst weeks and months after transplantation 
therefore, the number and dosages of the immunosuppressive drugs is highest during this 
early period. (Cotran et aI., 2000) 
The components of a standard immunosuppressive protocol include sirolimus or 
calcineurin inhibitors (cyclosporine, tacrolimus) and corticosteroid. Azathioprine and 
mycophenolate mofetil (MMF) are used in combination with a calcineurin inhibitor to 
enhance the potency of the immunosuppressive protocol. Agents to prevent infection are 
also used which include trimethoprim sulfamethoxazole (TMP-SMX) and antivirals. 
(Danovitch, 2001) 
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Immunosuppressant drugs can be classified into 4 groups: corticosteroids, anti-
metabolites, macrolides, and antibodies. 
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Table 1.1: Description of Currently used immunosuppressive agents (Watson et aI., 2005) 
(* mTOR - mammalian " Targets OfRapamycin" ) 
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1.4.1 Calcineurin Inhibitors 
Cyclosporine is a small cyclic peptide of fungal origin. (Suthanthiran and Strom, 1994) 
Its chemical structure has eight amino acids, with a molecular weight of 1,203 daltons. It 
is isolated from a strain of the fungi Hypocladium inflatum gams. (Vaden, 1997) 
Tacrolimus is a macrolide antibiotic extracted from Streptomyces tsukubaensis. It is a 23-
membered ring compound with a molecular weight of 804 daltons. (Vaden, 1997) 
These two immunosuppressant drugs have different structures but block T cell activation 
through similar mechanisms. Like cyclosporine, tacrolimus is highly lipophilic. Although 
there are some differences between these drugs they are however remarkably similar and 
both are highly effective. Tacrolimus is 10 to 100 times more potent than cycIosporine 
this may be due to the greater affinity for its binding protein. (Halloran, 2004) 
After entering the cytoplasm, calcineurin inhibitors form complexes with their 
immunophilins. The immunosuppressive effects of cyclosporine and tacrolimus depend 
on the formation ofa heterodimeric complex. (Suthanthiran and Strom, 1994) 
Cyc1osporine binds to cyclophilin and tacrolimus bind to the 12 kDa FK506- binding 
protein, FK binding protein -12. These complexes inhibit calcineurin activity and hence 
inhibiting the translocation of the NF A T family of transcription factors from the 
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cytoplasm to the nucleus of activated T -cells and thus hindering cytokine gene 
transcription. (Watson et aI., 2005) 
Inhibition of calcineurin blocks calcium-dependent T cell receptor signal transduction 
and subsequently inhibit de novo expression of nuclear regulatory proteins and T cell 
activation genes i.e. Cytokines like IL-2, IL-3, IL-4, IFN-y and TNF-a , proto-oncogenes 
e.g. H-ras and c-myc and receptors for cytokines e.g. IL-2 receptor. (Suthanthiran and 
Strom, 1994) Calcineurin inhibitors have recently been found to block the JNK and p38 
signaling pathways triggered by antigen recognition in T -cells. (Allison, 2000) 
Cyclosporine and tacrolimus have many similar side effects but there are also important 
differences. Both drugs are associated with nephrotoxicity and this is one of the most 
important side effects particularly after renal transplantation. (Sayegh et aI., 1999) 
Cyclosporine and tacrolimus both cause hyperkalemia, hyperuricemia, and the hemolytic 
uremic syndrome. Hypertension, hirsutism, hyperlipidemia and gum enlargement are 
more commonly observed with cyclosporine and may be improved by switching to 
tacrolimus. The two major adverse events associated with tacrolimus have been 
neurotoxic reactions and diabetes mellitus. Tacrolimus is more toxic to pancreatic islets 
than is cyclosporine. Neurologic manifestations include confusion, seizures, headaches 
and sleep disturbances. These fmdings tend to be dose related. Thus, close monitoring of 
blood levels and knowledge of dru~-drug interactions are important. (Cotran et aI., 2000) 
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The clinical use of cyclosporine is complicated because blood concentrations achieved 
after a specific dose vary from patient to patient and within each patient over time. These 
variabilities are largely determined by differences in absorption, distribution, and 
metabolism. Cyclosporine is metabolized by the hepatic P450 enzyme system. 
(Karamperis et aI., 2003) Several drugs interfere with cyclosporine metabolism and 
therefore may cause inadvertent overdosing or under dosing. Therefore to minimise the 
toxic effects of cyclosporine but maintain immunosuppression the dosage needs to be 
tailored to each patient. (Vaden, 1997) 
Cyclosporine is usually administered orally in a single dose or twice daily. (Cotran et aI., 
2000) Absorption may be enhanced when cyclosporine is administered with a fatty meal. 
The microemulsion formation of cyclosporine (Neoral®) has a better and consistent 
bioavailiability. The advantage of this formulation is that drug absorption is independent 
of bile flow or the presence of a fatty meal, absorption is thus more rapid and complete. 
(Sayegh et aI., 1999) 
Tacrolimus undergoes extensive metabolism by the P450 enzyme system. (Karamperis et 
aI., 2003) Tacrolimus has a narrow therapeutic index and it has poor aqueous solubility 
thus the absorption of oral tacrolimus is unpredictable and incomplete. The clearance of 
tacrolimus varies widely between patients. Increases in tacrolimus concentrations have 
been noted with concurrent administration of drugs such as erythromycin and 
methylprednisolone. Drugs shown to decrease tacrolimus concentrations include 
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dexamethasone and rifampin (Vaden, 1997) Thus it is important to monitor tacrolimus 
blood concentrations to optimise immunosuppression. (Zeevi et aI., 2001) 
1.4.2 mTOR Inhibitor (mammalian "Targets ofRapamycin") 
Rapamycin/sirolimus is a macrocyclic triene antibiotic which was originally isolated 
from the actinomycete Streptomyces hygroscopicus. (Allison, 2000) It is highly lipophilic 
and passes through cell membranes easily. The major immunosuppressive action of 
sirolimus is disrupting the proliferation signal by growth promoting cytokines. 
(MacDonald et aI., 2000) 
It is structurally related to tacrolimus and binds to the same cytosolic immunophilin, the 
12 kDa FK binding proteins. However, they work at distinctly different sites in the cell 
signaling pathway. The rapamycin and FK binding protein complex are highly specific 
inhibitors of mammalian target of rapamycin (mTOR). mTOR is a serine/threonine 
kinase involved in the phosphatidylinositol 3- kinase signaling pathway. Inhibition of 
mTOR has a profound effect on the cell signaling pathway required for cell-cycle 
progression and cellular proliferation. (Allison, 2000) 
This antiproliferative effect of sirolimus is not specific to T cells. It also inhibits the 
proliferation of B cells, fibroblasts, endothelial cells, and vascular smooth muscle cells. 
The ability of sirolimus to inhibit growth factor action in both immune and non immune 
cells is an important and distinguishing characteristic of this drug. (Cotran et aI., 2000) 
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The side effects of sirolimus are best categorised as metabolic, hematological, 
dermatological effects and effects related to growth factor inhibition. (Watson et aI., 
2005) Major side effects of sirolimus are thrombocytopenia, leukopenia and 
dyslipidemia. (Allison, 2000) Other effects include reduction in uric acid, and elevation 
in liver function tests. Skin rashes, particular acne, and mouth ulcers are more common in 
patients on mTOR inhibitors. (Watson et aI., 2005) 
1.4.3. Mode of Action 
The complex between cyclosporine-cyclophylin and Tacrolimus (FK506)-FKBP binds to 
and inhibits the function of the enzyme calcineurin which has a serine/threonine 
phosphatase activity. As a result, calcineurin fails to dephosphorylate the cytoplasmic 
component of the nuclear factor of activated T cells (NF-ATc), and thereby the transport 
ofNF-ATc to the nucleus and the binding ofNF-ATc to the nuclear component of the 
nuclear factor of activated T cells (NF-ATn). Consequently, T cells do not produce IL-2, 
which is necessary for full T-cell activation and proliferation. (Sayegh et aI. , 1999., 
Halloran, 2004) 
Sirolirnus inhibits late signals in T cell activation which are transduced by either the IL-2 
receptor or CD28 costimulatory signal transduction pathways. It inhibits the progression 
of the T cell into the S phase of the cell cycle. (MacDonald et aI. , 2000) In contrast, 
cyclosporine and tacrolimus interfere with the early events in T cell activation, blocking 
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Fig 1.6: Schematic representation of mechanism of action of cyclosporine, tacrolimus 
and sirolimus 
Therapeutic drug monitoring of immunosuppressant drugs are routinely performed 
however because of their narrow therapeutic ranges and the variation in blood levels of 
the drugs in different individuals and ethnicities there is no correlation between the 
amount of drug measured in the blood and the dose of drug administered. (Zheng et aI. , 
2005., Kowalski et aI. , 2003) 
The drug monitoring methods currently used do not take into account the effect that the 
administration of a combination of immunosuppressant drugs have on a patients' immune 
system. Certain drugs when administered together may be synergistic in that they work 
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together so the total effect is greater than the sum of the two (or more) or antagonistic in 
that they counteract or neutralise each others' effect. (Kowalski et aI. , 2006) 
Appropriate utilisation of immunosuppressants is important for the success of 
transplantation. It is therefore important to monitor the effect of these drugs on the 
immune system and control drug concentrations that are too high or too low which 
creates the risk of complications. (Shaw et aI. , 1999) 
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1.5 Complications of Immunosuppression therapy 
The immunosuppressant treatment necessary for long-term renal transplant function has a 
series of side effects. The major hannful consequences of long tenn immunosuppression 
are impainnent of the hosts' immune defenses against infections, malignancies and 
increases in cardiovascular complications which can be life threatening for the patient. 
(Andres, 2005., Kriesche et aI., 2003) Conversely, tapering of high levels of immune 
suppression results in antigen recognition and aBo-immune activation thus reducing 
immunosuppression carries with it the risk of rejection. (Sayegh and Carpenter, 2004., 
Chavez et aI., 2006) 
Data accumulated over many years confinns the association between immunosuppressive 
drugs with infection and malignancy. (Fishman and Rubin, 1998., Soulillou and Giral, 
2001) The leading cause of graft loss after the first year of transplantation today is 
premature death of the graft recipient due to infections which account for 11.7% of 
deaths and malignant conditions which account for 10.1 % of deaths. Cardiovascular 
diseases are responsible for 30.1%. (Sayegh and Carpenter, 2004) The risk of 
cardiovascular disease and stroke can be linked directly or indirectly to the 
immunosuppressive therapy because of its association with hypertension, hyperglycemia 
anemia and lipid disorders. (Kriesche et aI., 2003) 
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1.5.1 Rejection 
Immunologic reactions against kidney transplants have become less common as more 
specific immunosuppressive agents have evolved. However, rejection is still a concern 
for allograft loss. Rejection can be classified into hyperacute, acute and chronic. (Sayegh 
and Carpenter, 2004) 
1.5.1.1 Hyperacute rejection 
This is a rare and early episode of rejection that causes swelling, rupture, and loss of the 
allograft within minutes or hours post transplantation. It is thought to be caused by 
preformed antibodies to antigens present in the donor kidney. Hyperacute rejection can 
be fatal and requires removal of the graft. Currently used pre-transplant cross-matching 
techniques which test the recipient for pre-existing antibodies against the graft, has 
dramatically reduced the occurrence of this type of rejection. (Wood, 2006., Kobrzycki, 
1977) 
1.5.1.2 Acute rejection 
Acute rejection is an immunologic reaction against an allograft resulting in a rapid 
decline in renal function. Acute rejection usually occurs within one week or four months 
after transplantation. The majority of transplanted patients have at least one episode of 
acute rejection. (Kobrzycki, 1977) 
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Acute rejection typically manifests as a rapid rise in serum creatinine. Severe acute 
rejection episodes can cause fever, tenderness around the kidney and decrease in urine 
output. In some instances rapid weight gain, hypertension, an increase in proteinuria, a 
decrease in urinary sodium output and a decrease in creatinine clearance may occur. 
Histologically there may be extensive interstitial mononuclear cell infiltration, mild 
interstitial hemorrhage and oedema. (Cotran et aI., 2000) 
A study by Dharnidharka et aI., (2004) shows that the improvement in post transplant 
care and the development of more potent immunosuppressive agents has led to an 
impressive decrease in acute rejection rates. (Dharnidharka et aI., 2004) 
The relation between acute and chronic rejection is not clearly understood however acute 
rejection is considered an important predictor of chronic rejection. (Hariharan et aI., 
2000) 
1.5.1.3 Chronic rejection 
This is the most common cause of failure of long term allografts. (Ojo et aI., 2003) 
Chronic rejection is defined as an immunologic reaction against an allograft resulting in a 
gradual but persisting decline in renal function. Chronic rejection typically manifests as a 
gradual rise in serum creatinine, hypertension, decreasing creatinine clearance, and 
proteinuria. It is not a reversible process. (Kobrzycki, 1977) 
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Chronic rejection may be related to tissue injuries at the time of transplantation or during 
subsequent episodes of rejection and poor HLA matching. Using more living related 
donors and improving infection prophylaxis would lessen these two risk factors involved 
in chronic rejection. (Sayegh and Carpenter, 2004) 
Chronic rejection is diagnosed by findings from percutaneous needle biopsy of the kidney 
transplant. Chronic rejection is typified by a gradual obliteration of the lumen of small 
arteries in the graft caused by endothelial thickening further histologic features include 
thickening of the intima of arterioles and arteries, sclerosis of glomeruli, and tubular 
atrophy. When a transplanted kidney is rejected the patient returns to dialysis while 
waiting for another transplant. (Lopez et aI., 2006) The means of intervention or 
preventing chronic rejection remains a challenge. (Sayegh and Carpenter, 2004) 
Although newer immunosuppressive medications have greatly reduced the incidence of 
acute rejection the ideal therapy for both acute and chronic rejection would be to achieve 
a state of tolerance. Such a state will allow for indefinite allograft survival despite the 
recipients immune system being competent thus there would be no need for long term 
immunosuppression. (Sayegh et aI., 2001) 
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1.5.2 Infection 
Infection is one of the most important and common complications of renal 
transplantation. (Kobrzycki, 1977) Serious infectious complications develop in 15-44% 
of renal transplant recipient's within the first year of surgery. (Soulillou and Giral, 2001) 
Transplant patients are at increased risk for infections in the first 6 months after 
transplantation when immunosuppression is relatively high to prevent acute rejection 
however infections can occur at any time and can vary considerably in severity. (Jamil et 
aI., 1999) Infections add significantly to the morbidity and mortality of transplantation. 
Thus prevention of serious illness or death from infection depends on early detection. 
(Suthanthiran and Strom, 1994) 
Signs of infection include a feeling of discomfort, cough and sore throat. Fever is the 
most common sign of infection however due to depression of the immune system it may 
be absent. (Soulillou and Giral, 2001) 
When a transplant recipients' immune system is weakened they are susceptible to not 
only common bacteria that are encountered by surgical patients but also to opportunistic 
viral and fungal infections. (Kobrzycki, 1977) Post transplant infections can be caused by 
bacteria, viruses, fungi, mycobacteria, and other opportunistic microbes. Prophylactic 
treatment is administered to reduce the incidence of pulmonary infection (pneumocystis 
carinii) and urinary tract infections. Excessive immunosuppression also causes a 
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susceptibility to infectious diseases such as DNA viruses e.g. cytomegalovirus and 
Epstein-Barr virus (EBV). (Fishman and Rubin, 1998) 
It has been found that some immunosuppressive molecules interact in a synergistic 
manner with anti infectious agents to increase their effect. (Soulillou and Giral, 2001) 
Evidence from the studies by Neyts et aI., (1998) indicate that in addition to the level of 
exposure the type of drugs and the combinations used may be important variables 
affecting optimal prevention of viral infections in transplant recipients. (Neyts et aI., 
1998) Thus the solution may be to choose the best combination of therapies for each 
individual patient or complete drug withdrawal and induction of tolerance as suggested 
by Kasiske et al. (2000). (Kasiske et aI., 2000) 
1.5.3 Malignancy 
Cancer is a major complication of renal transplantation that causes significant short and 
long-term mortality. (Andres, 2005) It accounts for 30% of deaths of renal transplant 
patients. (Mahony et aI., 1995) Immunoregulatory mechanisms that normally protect 
against cancer development are suppressed by immunosuppression therapy therefore the 
risk of cancer in renal transplant recipients is twice that of age matched controls that have 
not had organ transplants as reported by Soullillou et aI., (2001) (Soulillou and Giral, 
2001) 
34 
A study by the Australian and New Zealand Transplant Registry (ANZTR) documents 
that kidney transplant patients have an increased risk of skin and non skin cancers and the 
risk of cancer increases with time and that many of the cancers that commonly occur in 
transplant recipients are virally mediated. Cincinnati Transplant Tumor Registry (CTTR) 
of transplantation found that the incidence of the rare non skin cancers which are rarely 
detected in the general population was greatly increased in transplant recipients. (Andres, 
2005., Soulillou and Giral, 2001) 
These types of cancer included lymphoma, lip cancer, Kaposi's sarcoma, carcinoma of 
the kidney, carcinoma of the vulva, cervix, esophagus and hepatic carcinoma. Cancers in 
transplant recipients were also found to be more aggressive and fatal than similar cancers 
in the general population. (Lopez et aI., 2006., Barret et aI. , 1993) 
Skin cancers are the most frequent type of malignancy occurring in renal transplant 
recipients. Immunosuppression and exposure to ultraviolet sunlight act synergistically to 
increase risk to cancer as well as viruses e.g. human papillomavirus (HPV), Epstein Barr 
Virus (EBV), Human Herpes Virus 8 (HHV -8) cytomegalovirus, hepatitis Band C 
viruses. (Kohrzycki, 1977) 
Non skin cancers that occur in renal transplant recipients are thought to occur as a result 
of latent viruses acquired from donor to recipient, during transplantation and activated by 
the collective immunosuppression. Post transplant lymphoproliferative disorder (PTLD), 
which is associated with EBV often progresses to non Hodgkins lymphoma which is the 
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second most common after skin cancers. Lymphomas are a major cause of cancer related 
mortality and morbidity. (Andres, 2005) 
It is generally believed that immunosuppression as a whole rather than particular 
immunosuppressive agents increases the risk of cancer in renal transplant recipients. This 
view is changing as evidence mounts suggesting that the immunosuppressive agents 
themselves affect the cancer risk. For example Hojo et aI., (1999) recently reported data 
suggesting that cyclosporine can increase cancer progression independent of its 
immunosuppressive effects in immune incompetent hosts. (Hojo et aI., 1999) Other data 
suggests that cyclosporine and tacrolimus might promote PTLD by enhancing the 
viability ofEBV infected B cells. (Beatty et aI., 1998) 
Since transplant patients typically require lifelong immune suppression the risks of 
rejection, cancer and infection associated with immunosuppressive agents continue to 
demand attention. Therefore to lower the risk of these complications the induction 
therapy and maintenance immune suppression regimen needs to be carefully controlled. 
Physicians strive endlessly to find the right balance between the level of 
immunosuppression required to prevent complications and the level that will minimise 
dose dependent side effects. (Soulillou and Giral, 2001) 
This could be achieved with the development of diagnostic tools for directly assessing the 
impact of changing therapies on the immune system. 
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1.6 ATP Bioluminescence Assay 
If transplantation is to be available with minimal risks and have optimal outcomes, 
challenges associated with immunosuppressive therapy need to be overcome. (Sayegh 
and Carpenter, 2004) In an editorial by Grimm P. (2006) he stated that many of the 
problems faced by transplant recipients will be improved by a test which determines 
overall cumulative immune suppression. (Grimm, 2006) 
A patients' immunologic response vanes as a result of the time since transplant, 
interaction with other drugs, drug metabolism (pharmokinetics), age, nutritional status, 
ethnicity, diabetes and stress. Currently there are no tests which look at the cumulative 
effect ofthese complex interactive factors. (Kowalski et aI., 2003., Israeli et aI., 2007) 
The tools currently available for assessing the status of a transplanted organ include 
monitoring the concentration of immunosuppressant in the blood or plasma, organ 
function tests e.g. measuring markers in the blood such as creatinine, absolute 
lymphocyte counts and histological evaluation of allograft biopsies which is the "gold 
standard" for assessing the status of allografts. (Kowalski et aI., 2006) 
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As a result of the pharmacokinetic differences between individuals the dose of a drug is 
not directly related to the levels measured in the blood and the test used targets a single 
drug which has limited value if the patient is on a multi drug regimen. (Kowalski et aI., 
2006) The main reason for drug monitoring of immunosuppressants is for preventing 
toxicity and measuring patient compliance not for preventing rejection or infection. 
(Caruso et aI., 2001., Kowalski et aI., 2006) 
It is difficult to predict the outcome of a transplant based on the morphologic information 
obtained from a biopsy. (Mannon and Kirk, 2006) A biopsy does not give an accurate 
reflection of the patients overall immune status. The invasiveness and risk linked with the 
biopsy procedure is a major hindrance. (Israeli et aI., 2007) 
The methods currently employed to measure T lymphocytes function include counting 
the number of T cells e.g. flow cytometry which requires expensive equipment, removal 
of culture media and performing a number of cell washes. Methods for measuring the 
proliferation of lymphocytes include radioactive thymidine incorporation, this technique 
requires several days to produce results and dangerous radioactive material. (Sottong et 
aI., 2000., Han and Bonventre, 2004., Kowalski et aI., 2003) 
The A TP bioluminescence assay is an in vitro assay. (Mollgard et aI., 2000) It quantifies 
the metabolic activity of the cell as a measure of their cellular A TP content. (Crouch et 
aI., 1993) 
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1.6.1 Adenosine Triphosphate (A TP) 
A TP is an important intracellular energy source present in all metabolically active cells. 
(Redsven et aI., 2007) All cells require A TP to remain alive and to carry out their 
specialised functions. (Crouch et aI., 1993) The amount of ATP in a specific healthy cell 
is relatively constant (Lundin et aI., 1986) thus cell injury (necrosis) and death 
(apoptosis) result in the rapid decrease in intracellular A TP. (Crouch et aI., 1993) A TP 
has been shown to correlate with an increase or decrease in proliferation. (White et aI., 
1989) Therefore A TP can be used as a tool to assess the functional integrity of living 
cells. (Slater, 2001., Dexter et aI., 2003) 
The main source of A TP used by cells comes from respiration or glycolysis. Immune 
cells use A TP for both the housekeeping functions and their individual activities. Energy 
in the form of A TP is needed for cation transport, macromolecule synthesis and processes 
involved in targeting antigens. Without adequate energy supply, suitable immune 
function would fail. This explains why processes of energy metabolism are important 
targets of immunotherapy. (Buttgereit et aI., 2000) ATP is an appropriate target for 
assessing the immune status of transplant patients on the immunosuppressants e.g. 
cyclosporine, tacrolimus and sirolimus as they are known to inhibit processes such as 
mitochondrial respiration that require cellular ATP. (Karlsson et aI., 1997) 
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A TP dependent cellular functions of immune cells such as lymphocytes and macrophages 
include intracellular synthesis of Iymphokines e.g. IL-2, transport, membrane insertion 
and release of receptors e.g. IL-2R and antigen presentation (Buttgereit et aI., 2000). 
1.6.2 Bioluminescence 
Photon-emitting chemistries have increasingly become the preferred choice for many 
types of experimental procedures in the biological and medical fields of study because of 
the availability of highly sensitive devices that are able to measure the light emitted. 
(Nakamura et aI. , 2006) The photon emitting chemistries are grouped according to the 
way the energy needed for photon generation is obtained. Examples include the most 
commonly used fluorescence which relies on photons as the energy source, 
chemiluminescence which relies on chemical energy, radioluminescence which relies on 
radioactivity and electroluminescence which relies on electricity. (Wood, 2007) 
Bioluminescence is a form of chemiluminescence (McElroy and Strehler, 1954) where 
the light yielding reaction is derived from a naturally catalysed process, found in glowing 
fireflies, jellyfish and bacteria. (Wood, 2007., Haneda and Johnson, 1958) 
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Dubois et aI., in 1885 reported on the first experiment concerning the nature of the 
components needed for bioluminescence. His experiments were carried out on the 
luminous organ of beetles. He found that bioluminescence depends on the presence of an 
enzyme substrate system including extracts of heat labile luciferase and heat stable 
luciferin components which emit light when mixed together. (Haneda and Johnson, 1958) 
This early work of Dubois R was continued by E. Newton Harvey and his associates at 
Princeton. (McElroy and Strehler, 1954) 
In 1947, McElroy demonstrated that the production of light by luciferase extracts from 
fireflies depends upon the presence of adenosine triphosphate (ATP). (McElroy and 
Strehler, 1954) The most well characterised firefly luciferase is that isolated from the 
North American firefly Photinus pyralis. (De Wet et aI., 1986) 
This enzyme reaction involves the mono oxidation of luciferin by firefly luciferase in the 
presence of A TP and Mi+ and oxygen. This reaction results in the production of 
oxyluciferin, adenosine monophosphate (AMP), inorganic pyrophosphate (PPi), CO2 and 
the emission of yellow-green light. (Squirrell et aI., 2002) Factors such as heat and low 
pH is known to affect the reaction. (De Wet et aI., 1986) 
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Fireflv Luciferase 
ATP + luciferin + O2 + Mg2+ - ~ AMP + PPi + oxyluciferin + C02 + light 
Fig 1.7: The luciferinlluciferase enzyme reaction (AMP: adenosine monophosphate, PPi: 
inorganic pyrophosphate, CO2: Carbon dioxide) 
Due to the sensitivity of the luciferin:luciferase system even small changes in A TP levels 
or changes in A TP levels in a small number of cells can be measured The light intensity 
from the reaction is proportional to the amount of ATP in the sample as little as 0.1 pg of 
ATP can be measured. (Redsven et aI., 2007) It can therefore deliver 10 to 1000 fold 
higher assay sensitivity than fluorescence assays. (Wood, 2007) 
Bioluminescent measurement of ATP has been used for assessing, cytotoxicity of cell 
lines and tumours and the quantification of biomass. (Bradbury et aI., 2000., Dexter et aI., 
2003) 
The success of organ transplantation relies on the ability to control the immune system. 
The A TP bioluminescence assay is proposed as a non invasive monitoring method of the 
immune system. (Chavez et aI., 2006) Therefore reported in this document are our 
observations on the use of an A TP bioluminescence assay as a tool to assess the immune 




• To adapt and optimise an A TP bioluminescence assay 
• To evaluate ATP bioluminescence as a potential tool to assess the effect of 
immune suppressant medication on the immune response in kidney transplant 
patients. 
Objectives 
• To describe the immune response distribution results obtained for the healthy 
individuals (control population) and patients on the immune suppressant drugs 
cyclosporine, sirolimus and tacrolimus. 
• To describe the correlation between immune response distribution and 
measurement of drug levels in the blood, immunosuppressant dosage, white cell 
count (WCC) and creatinine levels 
• To describe the association between immune response distribution, gender and 
time since transplantation. 
• To describe the immune response distribution of patients and their clinical status 
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2.1 Ethical consideration 
Chapter 2 
Materials and Methods 
This study has been approved by the Nelson R. Mandela School of Medicine, University 
of Kwa-Zulu Natal (UKZN), Biomedical Research Ethics Committee (BREC), Reference 
number: H172/05 and Postgraduate Education Committee. Reference number: PG049/07 
2.2 Patient population 
Patients were selected from the kidney transplant population attending the lnkosi Albert 
Luthuli Central Hospital (IALCH) renal transplant clinic. Patients who were on 
cyclosporine (n=22), tacrolimus (n=6) or sirolimus (n=lO) as part of their immune 
suppressant regimen were selected. The other types of medication included a steroid 
prednisone and mycophenolate mofetil or azathioprine. Informed consent was obtained 
from all participating patients (Appendix 9/11). A questionnaire (Appendix 6) was used 
to obtain patient history via personal communication with the patient and from their 
medical records. 
2.3 Control population 
Blood obtained from South African National Blood Services (SANBS-IO Eden Rd, 
Paradise valley, Pinetown, RSA) and blood samples kindly donated by known healthy 
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individuals was utilised. The control population included healthy male or female adults 
who are eligible to donate blood according to the blood donation guidelines. (Appendix 
8) Informed consent was obtained from all participating controls (Appendix 10111). 
2.4 Optimisation 
The following parameters were investigated to ensure optimal results. The intracellular 
ATP content of 2500, 5000, 10 000, 50 000, 100 000 and 200 000 PBMC's were 
analysed after a 24 incubation period. Stimulation of cells by Phytohemmagglutinin 
(PHA) (Sigma®, Capital laboratory, New Germany, Dbn, RSA) prepared according to 
the manufacturers instructions (Appendix 5) to final concentrations of 1 f.1g/ml, 5 f.1g/ml 
and 10 f.1g/ml were investigated. 
2.5 Sample collection 
The control and patient whole blood specimens were collected in 4 ml purple top EDTA 
vacutainer tubes with the help of phlebotomist at the IALCH renal transplant clinic. 
Each tube was dated and labeled with the patient name, hospital number and 
immunosuppressant taken by the patient. The tubes were gently inverted several times to 
ensure uniform distribution of blood cells and to ensure the blood mixed thoroughly with 
the anticoagulant. PBMC retrieval was completed within 30 hours of specimen collection 
and the blood collection tubes were stored at room temperature (l8-25°C) before 
processing. This allowed good separation of the desired cells and subsequent cell 
proliferation. (Fitzgerald, 1972) 
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2.6 Peripheral blood mononuclear cell (PBMC) isolation 
The technique of separating peripheral blood mononuclear cells (PBMC's) from whole 
blood was developed over 30 years ago (Boyum, 1968). Lymphocytes and monocytes can 
be selected from a variety of subjects and are used to study a variety of diseases. (Boyum, 
1977) The technique for lymphocyte and monocytes separation used in this study was 
based on their density differences. 
Approximately 4 ml of anticoagulated whole blood from each vacutainer tube was 
transferred to 15 ml centrifuge tubes and centrifuged at 2000 rpm for 10 min. The plasma 
fraction which formed following centrifugation was removed using a fine tip Pasteur 
pipette and dispensed into 2 ml nunc vials. 
Thereafter phosphate buffered saline (PBS) (Whitehead Scientific (pTY) Ltd, Brakenfell, 
Cape Town, RSA) was added in a ratio of 1:1 or according to the amount of plasma 
removed. The 15 ml centrifugation tube was inverted a few times to ensure mixing and 
even distribution of the blood cells and PBS. 
Histopaque 1077 (Sigma®, Capital laboratory, New Germany, Dbn, RSA) was gently 
dispensed into a sterile 15 ml polypropylene tube and allowed to warm up to room 
temperature. The blood and PBS mixture was gently layered onto the histopaque making 
sure not to break the interphase of the density gradient. The tubes were spun at 1400 rpm 
for 30 min at room temperature. 
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This resulted in the separation of the blood into its different cellular components 
according to their differences in density. The PBS, plasma fraction formed at the top of 
the tube followed by the mononuclear cells (buffy coat), the histopaque 1077, the 
granulocytes and the red blood cells (RBC) (Appendix 1). The PBS, RBC's and 
granulocytes fractions were discarded according to standard safety procedures. 
The mononuclear cell layer was aspirated and place in a sterile 15 ml centrifuge tube and 
washed to remove residual histopaque. This was done by adding approximately 8 ml of 
PBS and centrifuged at 1500 rpm for 10 min at room temperature. Following the first 
wash step the mononuclear cell formed a pellet at the bottom of the tube this was 
resuspended in PBS and the washing step was repeated two more times Sterile distilled 
water was used to remove any contaminating RBC's and platelets in the pellet 
(Appendix 4). 
Thereafter the pellet was immediately suspended in 1 ml Roswell Park Memorial Institute 
(RPM!) 1640 medium supplemented with 10% fetal calf serum (FCS) (Highveld 
Biological (pTY) Ltd, Lyndhurst, Jhb, RSA) and HEPES, L-glutamine, penicillin, and 
streptomycin (Whitehead Scientific (PTY) Ltd, Brakenfell, Cape Town, RSA). Aseptic 
techniques, a laminar flow cabinet and 70% ethanol and bleach were used, to prevent 
contamination. 
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2.7 Cell counting 
The PBMC' s suspended in 1 ml RPM! 1640 medium supplemented with 10% foetal calf 
serum (FCS) were thoroughly vortexed and 10JlI of cells were transferred to a Neubauer 
hemocytometer. The solution filled the area under the cover slip by capillary action. The 
counting grid was brought into focus on low magnification (lOX). The cells in the four 
comer squares were systematically counted (refer to Figure 2.8). Precaution not to 
overload the chamber or move the cover slip was taken to prevent an inaccurate count. 
The cells were counted with the hemacytometer to ensure a uniform number of cells were 
used and to maintain consistency in the assay between patient samples. 
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Fig 2.8: Hemacytometer counting chamber. Areas marked A, B, C, and D are used to 
count white blood cells. 
The number ofPBMC's per ml were calculated using the equation 
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PBMC counted in each block x 104-Volume conversion factor to 1ml 
4 
e.g. 185+200+240+175114 x 10000 = 2000000 cells/ml 
If cells were for example suspended in 5ml (5000IlI) of RPMI 1640 medium 
supplemented with 10% FCS, the total number of cells in 5 ml were calculated by 
multiplying the number of cells obtained per ml by the cell suspension volume i.e. 2 000 
000 x 5000lli therefore you have 10 000 000 cells in 5000lli. 
50 000 cells were required per well, cells enough for 20 wells were taken i.e. a total of 1 
x 106 cells were removed from the cell suspension. The amount of the cell suspension 
that contained 1 x 106 was calculated (lxl06.10001l1/2x106=5001l1) which was suspended 
in 1100lli ofRPMI and 10% FCS to make up 1,6 ml. Adding 80111 of this suspension to 
each well of a 96 well plate transferred 50 000 cells to each well. 
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2.8 Peripheral blood mononuclear cell (PBMC) stimulation 
Lymphocytes separated from peripheral blood are stimulated by a commonly used 
mitogen, phytohemagglutinin (PHA) to proliferate. PHA is a plant lectin extracted from 
red kidney beans (Phaseolus vulgaris). PHA consists of two closely related proteins, 
called PHA-L and PHA-E. The letters Land E indicate that these proteins agglutinate 
leukocytes and erythrocytes respectively. As a mitogen PHA is able to trigger cell 
division (mitosis) in T -lymphocytes, however it produces a greater stimulatory effect on 
CD4 T lymphocytes than on CD8 T cells. (Ozerol et aI., 1996) 
PHA affects the permeability of the cell membrane to transport proteins. When T cells 
interact with PHA the metabolic activity of the cells increase and this increase is reflected 
in a significant increase in ATP levels. In this study PHA-M (mucoprotein) which is a 
mixture of glycoproteins found in the red kidney was used. (Nowell, 1960., Hamelryck et 
aI., 1996., Forsdyke, 1967) 
The white opaque 96 well polystyrene microtiter solid bottom assay plate (Cellstar, Lasec 
SA (PTy) Ltd, Marine parade, Dbn, RSA) was assembled so as to include one strip for 
the control sample, one strip for each patient sample and one strip for the A TP standard. 
80 J..lI of culture media (RPM! with 10% FCS) containing approximately 50 000 cells 
were plated into the wells of each assay plate strip. White opaque 96 well solid bottom 
assay plates were used to prevent cross talk between wells and prevent the loss of 
luminescence signal which occurs with standard clear 96 well assay plates. 
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For the purpose of assessing ATP synthesis in response to the stimulant and the basal 
ATP activity, the first 3 wells of each of the patient strips and control strip were 
designated as non-stimulated wells (negative controls, wells 1-3), 20 f.11 of RPM! 1640 
medium with 10 % FCS was added to these wells while 10 f.11 of RPM I 1640 and 10 f.11 of 
the mitogen, PHA solution (Sigma®, Capital Lab Supplies, New Germany, Dbn, RSA) at 
a final concentration of 1 f.1g/ml was dispensed into the next 3 wells, designated as 
stimulated wells (wells 4-6). (Refer to Figure 2.9) 
The effects of incubating patient and control PBMC' s with plasma isolated from the 
patients' blood samples and plasma from healthy individuals' blood samples was also 
investigated. In wells 7 to 12 of each patient and control strip containing 80 f.11 of 
PBMC' s, 10 f.11 ofPHA solution was added. Followed by 10 f.11 of plasma from a healthy 
control which was added to three ofthe six wells (wells 7-9) and 1Of.11 of plasma from the 
patient was added to the remaining three wells (wells 10-12). 
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Fig 2.9: Schematic representation of the plate map for the patient and control samples and 
A TP standard 
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Wells containing culture media only (blank) were used as a control to measure 
background luminescence i.e. A TP contamination. The background luminescence was 
subtracted from all readings. 
Ultimately all the wells had an equal volume of 100 ,.tI. The assay plate was then 
incubated overnight (15-18 hours) in a 37°C, 5% CO2 incubator. Following incubation 
the 96 well microtiter assay plate was removed from the incubator, and equilibrated to 
room temperature for approximately 30 min. 
2.9 ATP standard 
The A TP (Sigma®- Capital Laboratory, New Germany, Dbn, RSA) standard was 
prepared by serial dilutions of 1 mg A TP according to manufactures instructions to 
concentrations of 10000 nglml, 1000 nglml, 100 nglml, 10 nglml and 1 nglml with 
distilled water. 100 III of each level of the calibrator panel were dispensed into the 
designated wells (Refer to Figure 2.9). The amount of A TP produced is calculated from 
the A TP standard curve thus an A TP standard was run which each assay plate and a 
standard curve is generated for each test. 
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2.10 CellTiter Glo® Luminescent cell viability assay (promega-Wbitehead 
Scientific (PTY) Ltd, Brakenfell, Cape Town, RSA) 
This test is a uniform single step method of determining the number of metabolically 
active cells in culture based on the amount of A TP detected. Intracellular A TP is 
measured using the firefly luciferinlluciferase reaction. This assay uses a stable form of 
luciferase based on the gene from the firefly Photuris pennsy/vanica. A mutant form of 
the gene was created in which the characteristics that improve performance were 
selected, eliminating the problems caused by endogenous ATPases, pH, detergents and 
hence creating a reagent that has a sensitive and stable luminescence. The luminescence 
generated is proportional to the number of viable cells. The Cell Titer Glo assay reagent 
was prepared according to manufactures instruction. (prom ega, 2005) 
An equal volume of 100 JlI of the Cell Titer Glo® assay reagent equal to that of the cell 
culture medium used, was dispensed into each well. The plate was then shaken on the 
Labnet Orbit P4 microplate shaker (Whitehead Scientific (PTY) Ltd, Brakenfell, Cape 
Town, RSA) for 2 min at 900 RPM to induce cell lysis and release the intracellular ATP 
to react. The cells were then incubated for 10 min at room temperature to stabilise the 
luminescent signal. 
The cells were read with the GloRunner™ Microplate Luminometer (Whitehead 
Scientific (pTY) Ltd, Brakenfell, Cape Town, RSA, Turner Biosystem) at a wavelength 
of 550 nm for 1 sec per well. Luminescence was recorded in relative light units (RLU). 
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Turner Biosystems Glorunner™ microplate luminometer software was used to access and 
analyse the results. 
2.11 Construction of an ATP standard curve 
Microsoft Excel® program was used to draw up the standard curve. The average of the 
triplicate RLU readings for each known A TP dilution concentration was calculated. The 
Standard Curve was drawn with the known ATP concentration value on the X axis and 
the calculated RLU value on the Y axis. The straight line equation y=mx+c was used to 
determine the A TP values of the test samples. 
2.12 Data analysis 
A statistician (Ms Fikile Nkwanyana, College of Health Sciences, Tel: +27 31 2604792) 
was consulted for help regarding the statistical analysis of the results. The data was 
analysed using a commercial statistics program (Graph pad prism 4). This is a descriptive 
study thus intra group statistics such as, mean, standard error of mean (SEM), median and 
minimum and maximum values were used to summarise the data. Chi-square test was 
employed to assess the statistical significance of differences between means. Values were 




3.1 The format of the A TP bioluminescence Assay 
~t °03 ~ -+ --- ° . • Incubate 
Count cells to Lymphocyte 
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isolation stimulation Glo® Luminescent 
amount 
cell viability assay 
Quantification of ATP production 
Fig 3.10: Format of the ATP bioluminescence Assay 
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3.2 Optimisation results 
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Fig 3.11: A TP standard curve (RLU vs. ATP ng/ml) 
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Fig 3.14: Changes in ATP level in PHA stimulated PBMC's cultured for 24,48 and 72 
hours 
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Table 3.2: The effect of various PHA concentrations on lymphocyte proliferation 
PHA concentration Unstimulated cells Stimulated cells Amount of A TP produced 
PBMC's only PBMC's+PHA 
in response to stimulant 
PHA after subtracting the 
(A TP nglml - to measure (ATPnglml) basal A TP value 
basal ATP) 
O,...g/ml 2852 nglml - -
1 J12/m I - 3193 ngimI 341 ng/ml 
5J12/ml - 2959 nglml 107 ng/ml 
lOJ1g/ml - 2817 nglml -35 ng/ml 
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3.3 Clinical testing demographics 
Table 3.3: Clinical testing demographics of kidney transplant patients 
Kidney Transplant Patients 
Cyclosporine Sirolimus Tacrolimus 
Number %of Number % Total Number of %of 
of Total of Samples Total 
Samples Samples 
Gender 
Males 10 45 5 50 4 66 
Females 12 55 5 50 2 33 
Unknown - - - - - -
Total 22 100 10 100 6 100 
Ethnicity 
Asian 14 64 6 60 4 66 
African 2 9 4 40 1 17 
Caucasian 4 18 - - 1 17 
Coloured 2 9 - - - -
Unknown - - - - - -
Total 22 100 10 100 6 100 
Age ran2e(yrs) 39-68 19-64 15-38 
Average Age 53.5 41.5 26.5 
Time since Transplant 
< 1 year - - - - 1 20 
1-10 years 11 50 8 80 5 40 
> 10years 11 50 2 20 - -
Unknown - - - - - 40 
Total 22 100 10 100 6 100 
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Table 3.4: Clinical testing demographics of control population 
Healthy Controls 
Number of Samples % of Total 
Gender 
Males 5 33 
Females 5 33 
Unknown 5 33 
Total 15 100 
Ethnicity 




Unknown 5 33 
Total 15 100 
A~e ran~e (years) 18-64 
Average Age 41 
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3.4 The ATP bioluminescence assay results 
Table 3.5: Immune response results obtained with the ATP bioluminescence assay in the 
control group, cyclosporine, sirolimus and tacrolimus groups (Chi square test was used to 
determine statistical significance of means) 
Unstimulated Stimulated Amount of % increase p-value 
ATPng/ml inATP (Control vs. 
PBMConly PBMC+PHA produced following immunosuppressant 
(ATPng/ml) (ATPng/ml) following stimulation groups) 
(measure of basal stimulation 
ATP activity) 
Control 2988±SEM216 4235±SEM 1247± SEM 47.69±SEM 
236 132.2 7.24 
Cyclosporine 2406± SEMI 75 2649±SEM 243±SEM 11.40± p<O.OOl 
178 26.56 SEM 1.67 
Sirolimus 2250± SEM242 2505±SEM 255±SEM 11.99± p<O.OOl 
255 44.39 SEM 1.88 
Tacrolimus 2325±SEM 470 2691±SEM 366±SEM 21.62± p<O.OOl 
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Fig 3.15: The average ATP produced following PHA stimulation of lymphocytes in the 
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Fig 3.16: Evaluation of the immune response distributions between the control population 
(n=15) and all the kidney transplant patients included in the study (n=38) 
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Table 3.6: Statistical comparison of the immune response results according to the gender 
of transplant recipients and control population. (NS:not significant) 
Control Transplant Recipient 
Population Cyclosporine Sirolimus Tacrolimus 
Mean p Mean p Mean p Mean p 
Value Value Value Value 
Gender Male 911 P<0.05 225 NS 319 P<O.OOOI 424 P<O.OOOI 
(n=5) (0=10) (n=5) (n=4) 
Female 1051 259 191 250 
(n=5) (n=12) (n=5) (n=2) 
unknown 1778 - - -
(n=5) 
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Fig 3.24: Assessment of the immune response distribution according to white cell count 
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Fig 3.25: Immune cell response range vs. time since transplantation 
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Table 3.7: Evaluation of the immune response ranges and the clinical outcomes of 
transplant recipients 
ATP levels Stable Infection rejection 
(ng/ml) 
>525 (n=3) 2 - I 
524-225 (n=20) 15 5 -









Patient1 Patient2 Patient3 Patient4 Patient5 
Test 1 497 306 342 260 397 
• Test 2 294 50 104 264 119 
o Test 3 312 213 187 312 402 
Fig 3.26: Immune response distribution of patients (n=5) over 3 months. (Low: <200, 
Moderate: 201-500, Strong: >501) 
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3.5 Evaluation of ATP bioluminescence Assay including plasma 
Table 3.8: Immune response results obtained with the ATP bioluminescence assay in the 
control group, cyclosporine, sirolimus and tacrolimus groups in the presence of plasma 
isolated from the patients' blood (Chi square test was used to detennine statistical significance of 
means) 
Unstimulated Stimulated Amount of % increase/ 
ATP (ng/ml) decrease in 
PBMC only PBMC+PHA + 1 Olll produced ATP 
(ATPnglml) patient plasma following following 
(measure basal ATP 
(ATPnglml) stimulation stimulation 
activity) 
Control 2988 3762 774 30.5 
±SEM216 ±SEM 196 ±SEM59.16 ±SEM5.0 
Cyclosporine 2406 2510 48 3.4 
±SEMI75 ±SEM207.5 ±SEM 114.2 ±SEM 6.3 
Sirolimus 2250 2336 86 4.1 
±SEM242 ±SEM229.5 ±SEM202.7 ± SEM 13.4 
Tacrolimus 2325 2149 -176 6.2 
±SEM470 ±SEM 100.5 ± SEM426.5 ±SEM28.1 
78 
f .iOle 3.9: immune response resuits obtained with the ATP bioiuminescence assay in the 
control group, cyclosporine, sirolimus and tacrolirnus groups in the presence of plasma 
isolated from the blood of healthy individuals (Chi square test was used to determine statistic:!1 
significance of means) 
I Unstimulated I Stimulated 
I I 
PBMConly PBMC+PHA + 1O~1 
(ATPnglm!) control plasma 
(measure basal ATP 
(ATPnglmi) 
activity) 
Control 2988 3313 
±SEM216 ±SEM 200.1 
Cyclosporine 2406 1915 
±SEM175 ±SEM 149.9 
Sirolimus 2250 1834 
± SEM242 ±SEM 151.4 
Tacrolimus 2325 1252 
±SEM470 ±SEM64.07 
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Transplant recipients requITe lifelong immune suppression medication to prevent 
rejection. During personal communications with the patients included in this study, side 
effects of the medication/immune suppressants administered was cited as their number 
one concern. 
A comment made by one of the patients was that ''taking the medication is like a double 
ended sword, on the one hand it helps with making the new kidney work while on the 
other it makes us very sick, the side effects will be the end of me rather than my donors' 
kidney!" Some of the debilitating ailments mentioned by the patients included skin 
cancer, increase in hair growth, darkening of the skin, increase in acne, bone dystrophy 
requiring hip replacements, diarrhea, decrease in appetite, dental and gum complaints, 
loss of weight and palpitation. 
This comment re-emphasised that there is a dire need for better diagnostic tools to 
monitor immune suppression and prevent the development of such complications and 
ultimately improve the transplant recipients' quality of life. 
Thus the aim of the study was to evaluate the A TP bioluminescence assay as a potential 
diagnostic tool to assess the effect of immune suppressant medication on the immune 
response in a cross section of the transplant patient population attending IALCH renal 
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transplant clinic. Ultimately the study explores A TP as a determinant of viability and 
thus the level of immune suppression of lymphocytes. 
As shown in figure 3.1 0 the steps involved in the A TP bioluminescence assay included 
isolation of peripheral blood mononuclear cells which were counted to a specific number 
and plated and incubated overnight with and without the stimulant PHA, following which 
the intracellular A TP content of the lymphocytes was measured with the use of the 
CeliTiter' Glo® luminescent cell viability assay which lysed the cells to release the 
intracellular A TP and produce light via the luciferinfluciferase enzyme reaction. 
The luminescent signal was read by a luminometer. The concentration of A TP (nglml) 
was calculated from a standard curve that was run with each assay plate. Hence, the assay 
looks at the ability of lymphocytes to function according to their response to a mitogen 
and subsequent A TP production. 
Although the method to culture peripheral blood mononuclear cells is well established 
(Boyum, 1968) the measurement of lymphocyte intracellular A TP to determine immune 
function via bioluminescence with the use of a luminometer to my knowledge, is not well 
established in the South African context. 
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The following components of the assay were optimised before subjecting patient samples 
to the assay these included generating a standard curve with a suitable range of A TP 
(ng/ml) values, testing different incubation periods, investigating a range of PHA 
concentrations to obtain one that elicited sufficient proliferation of T cells and evaluating 
the production of ATP (ng/ml) by varying concentrations ofPBMC's. 
An A TP standard was included in each microtiter plate in order to generate a standard 
curve from which the intracellular A TP levels of control and patient test samples could be 
directly calculated after each assay run. The relative light units (RLU) measured for 
control and patient samples were converted to ATP (ng/ml) based on equivalent RLU 
values in the ATP standard curve. As depicted in Figure 3.11 the known ATP ng/ml is 
plotted on the X axis and the amount of light produced measured in relative light units 
(RLU) on the Y axis. The ATP standard ranged from 1 ng/ml to 10000 ng/ml. To assess 
linearity of the curve the correlation coefficient (?) was calculated. 
Our findings correlated with previous studies that showed that the measure of 
intracellular A TP is directly proportional to the number of living cells in the sample. 
(Ishizaka et aI., 1984., Bulanova et aI., 1995., Kangas et aI., 1984) 
The relationship between RLU which is a measure of the intracellular A TP detected by 
the luminescent signal and the number of cells in culture showed a linear relationship 
(?= 0.99). Conversion of the RLU values to the corresponding A TP (ng/ml) values with 
the A TP standard curve calibrations confirmed that this assay exhibited a linear 
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correlation between A TP produced and the increasing concentrations of cells i.e. 2 500 to 
200 000 (refer to Figure 3.12 and 3.13). This finding highlights the sensitivity of the 
ATP bioluminescence assay. 
The increase in A TP in response to the stimulant PHA was measured after incubation 
periods of one (24 hr), two (48 hr) and three (72 hr) days. An increase in ATP production 
was demonstrated over the three incubation periods. There was a 198 nglml ATP level 
increase after a 24 hour culture, after 48 hours there was a slight increase to 252 nglml of 
A TP and after 72 hours of culture a marked increase in the A TP level (562 nglml of 
A TP) was found (refer to figure 3.14). A 24 hour incubation period was selected for the 
study because a change in A TP levels is able to be measured within approximately 24 
hours as depicted above which is relatively short time period in comparison to other 
proliferation tests which require 3-10 days e.g. radioactive thymidine incorporation 
(Assounga and Jones, 1996). 
A study by White et aI., (1989) illustrated that there are early changes in the levels of 
intracellular A TP in mitogen stimulated lymphocytes. Under the influence of the 
mitogen, T lymphocytes undergo activation which includes the clustering of surface 
receptors, increased uptake of metabolites and ions and increased metabolism of 
phospholipids. These initial events are followed by DNA synthesis, synthesis of 
cytokines and fmally mitosis. (White et aI., 1989) These processes require ATP hence 
increases in intracellular ATP levels induced by mitogens in lymphocytes is related to 
cell activation. (Buttgereit et aI., 2000., Sottong et aI., 2000) 
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The mitogen phytohemagglutinin (PHA) was used as it is a potent stimulus and allows 
the study of the functional activity of lymphocytes in vitro as it is able to elicit a response 
in even highly suppressed lymphocytes. (Kowalski et aI., 2003) Table 3.2 shows the 
results of testing various concentrations ofPHA; it was found that high concentrations 
(5 Jlglml, 10 Jlglml) of PHA-M exhibited a toxic effect in the stimulated test wells in 
comparison to non stimulated cells. That is 107 nglml and -35 nglml of A TP which is less 
than the basal level of A TP was measured in response to 5 Jlglml and 10 Jlglml 
concentrations ofPHA respectively. A significant increase in ATP (ng/ml) was measured 
in response to a lower dose of PHA (1 Jlglml) following 24 hour incubation (ie. 341 
nglml). Hence 10 Jll of PHA at a final concentration of 1 Jlglml was used. (Bulanova et 
aI. , 1995) 
Table 3.3 and table 3.4 summarises the demographics of the populations included in the 
study. 38 kidney transplant patients and 15 apparently healthy adults were recruited. The 
inclusion criteria for controls were apparently healthy male and females of different 
ethnicities i.e. Indian, African, Caucasian and Coloured between the ages of 18 and 64 
who were able to donate blood according to the blood donation guidelines. 
The inclusion criteria for the transplant recipients were men and women of different 
ethnicities i.e. Indian, African, Caucasian and Coloured between the ages of 15-70 years 
who were recipients of a cadaver, living related or living unrelated kidney transplant. The 
inclusion criteria were not restricted by the time period since the transplant or the type of 
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immunosuppressant regimen. The dosage of the different immunosuppressant drugs 
varied within and between patients. 
The nature of patients recruited is a reflection of the dynamics of the patients attending 
the IALCH renal transplant clinic. Majority of the transplant population are of the Indian 
race and majority of the patients are on cyclosporine that is approximately 200 in 
comparison to approximately 30 on sirolimus and approximately 10 patients on 
tacrolimus. 
Table 3.5 represents the immune response results obtained with the ATP bioluminescence 
assay in the control group, cyclosporine, sirolimus and tacrolimus groups. For each of the 
groups both stimulated and non-stimulated PBMC's test wells were included for each test 
sample. 
The average ATP (ng/ml) measured for the unstimulated PBMC's in the apparently 
healthy controls group was 2988 ng/ml (n=15, ±SEM216) and the mean ATP (ng/ml) 
measured for the unstimulated PBMC's of the kidney transplant patients on the immune 
suppressants cyclosporine was 2406 ng/ml (n=22, ±SEM175), sirolimus 2250 ng/ml 
(n=lO, ±SEM242) and tacrolimus 2325 ng/ml (n=6, ±SEM470). 
Statistically significant difference was measured between the mean unstimulated A TP 
(ng/ml) result of the control group and the unstimulated ATP (ng/ml) results of each of 
the immunosuppressant drug groups (p<0.001), no statistical significant result was 
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measured between the drug groups. The unstimulated PBMC's tested in the control group 
produced on average 661 ng/ml more ATP than the unstimulated PBMC's tested in each 
of the drug groups. 
The mean ATP production compared between stimulated PBMC's in apparently healthy 
controls (n=15, mean:4235 ng/mIATP, ±SEM236) and kidney transplant patients on the 
immune suppressants cyclosporine (n=22, mean:2649 ng/mIATP, ±SEM 178), sirolimus 
(n=lO, mean: 2505 ng/mIATP, ±SEM255) and tacrolimus (n=6, mean:2691 ng/ml ATP, 
±SEM50 1) differed by on average 1620 ng/ml A TP. 
Statistically significant difference was measured between the mean A TP (ng/ml) results 
of the stimulated cells in the control group and the mean A TP (ng/ml) results of the 
stimulated cells in each of the immunosuppressant drug groups (p<0.001), no statistical 
significant result was measured between the drug groups. 
In view of the fact that all somatic cells contain A TP and will therefore exhibit a baseline 
level of ATP, unstimulated test wells were set up for each test sample to measure basal 
ATP activity. We therefore proposed that calculating the difference between the 
unstimulated and stimulated results was a measure of the A TP produced by lymphocytes 
that were activated to proliferate in response to PHA, this value was used to characterise 
the immune response of the individuals tested. The percentage increase between 
unstimulated cells and stimulated cells was also calculated. 
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Figure 3.15 depicts the average increase in ATP (ng/ml) by lymphocytes in response to 
PHA stimulation. Each dot represents the results of the individuals tested. The mean 
increase in A TP (ng/ml) by lymphocytes in response to PHA stimulation in the group of 
healthy donors was 1247 ng/ml (±SEM132.2, median: 1200, min: 471 , max: 2431) with a 
percentage increase of 47.69% (±SEM 7.24) 
The mean increase in ATP (ng/ml) by lymphocytes in response to PHA stimulation in the 
cyc1osporine group was 243 ng/ml (±SEM26.56, median:263, min: 13, max:497) 
compared to 255 ng/ml (±SEM44.39, median:256, min:121 , max:564) and 366 ng/ml 
(±SEM109.0, median:336, min:78, max:677) increase in ATP for the sirolimus and 
tacrolimus groups respectively. Cyc1osporine had a percentage increase of 11.4% while 
sirolimus and tacrolimus had percentage increases of 11 .99% and 21.62% respectively 
Statistically significant difference was measured between the mean increase in ATP 
(ng/ml) calculated for the control group and each of the immunosuppressant drug groups 
(p<0.001). No statistically significant difference was measured between the mean 
increase in ATP measured for the cyc1osporine and sirolimus groups. These two 
immunosuppressant drugs appear to have a similar immunosuppressive effect (potency) 
on patients' immune system despite the fact that the mode of action on lymphocytes 
differ. 
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A statistically significant difference was measured between the tacrolimus group and the 
cyclosporine as well as the sirolimus group. Tacrolimus treated patients demonstrated on 
average 123 nglml and 111 nglml (A TP) stronger response to PHA stimulation than the 
cyclosporine and sirolimus treated patients respectively. However it must be noted that 
fewer patients who received tacrolimus (n=6) based regimen was included in the study. 
Bearing in mind tacrolimus is considered to be a more potent immune suppressant drug 
(Kowalski et aI., 2003) in comparison to the other two test drugs because of its' greater 
affinity for calcineurin, one would have expected the results to reflect the opposite i.e. 
lower lymphocyte response to PHA stimulation. A possible explanation for these results 
is the age of the patients who were recruited in this group. They were fairly young, an 
average age of 26 years old with the youngest being 15 and oldest 34 in comparison to 
patients in the other drug groups, cyclosporine with an average age of 53 years old and 
sirolimus 41 years old. It has been documented that as one ages the immune system 
weakens, and another contributing factor could be the fact that the patients in the 
tacrolimus group were made up of more recent transplants, less than 10 years old, hence 
having a stronger immune response. (Tsukada et aI., 1999., Martins et aI., 2005) 
Overall the immune response results of the kidney transplant patients (n=38) which 
averaged 266 nglml (±SEM 25.75, median 263, min 13, max 677) was significantly 
statistically lower (p<0.0001) than healthy controls by 981 nglml of ATP (refer to Figure 
3.16). 
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Table 3.6 illustrates the comparison between ATP (ng/ml) measured and gender of 
transplant recipients and apparently healthy controls. The immune response of males and 
females transplant recipients were not statistically different in the cyclosporine 
population (P=O.2742) however in the tacrolimus and sirolimus patient groups statistical 
significant difference was measured (P<O.OOOI). 
Male patients showed a 34 ng/ml lower ATP level than females in cyclosporine group 
this same trend is not seen in the sirolimus and tacrolimus groups where males had a 
128 ng/ml and 174 ng/ml respectively higher ATP level than their female counterparts. 
The dosages of immunosuppressant drugs administered to the male and female patients in 
the sirolimus and tacrolimus groups were analysed to determine if they differed to 
explain the statistical significant difference in the mean A TP (ng/ml) measured for 
patients in these drug groups. No major difference was observed, male patients were not 
given higher or lower doses of immunosuppressant drugs in comparison to their female 
counter parts. 
However, the small size of the sample of patients in the sirolimus and tacrolimus groups, 
dictates that no clinical significance should be drawn from these results unless they are 
confirmed in a larger patient sample. 
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Healthy male controls gave statistically significant lower (p<0.05) immune responses 
than females by 140 ng/ml ATP. Females are known to have a more active immune 
system than males. They have significantly higher numbers of CD4 T lymphocytes than 
males, which most probably contributes to their increased immune response. 
Unfortunately, in some individuals their immune responses are exaggerated to such an 
extent that it leads to the development of autoimmune diseases e.g. systemic lupus 
erythematosus (SLE) which has a female to male ratio of approximately 9: 1. (Whitacre, 
2001., Trune and Kempton, 2002) 
In this study we did not investigate the differences between ATP production and patients 
of different ethnicities, because the majority of the patients attending the IALCH renal 
transplant clinic and hence recruited into this study were of the Asian/Indian designation. 
However, it is important to investigate this issue in future studies, more insight into 
ethnicity dependent variations of A TP production could support individualised immune 
suppression strategies. 
Measuring the level of immunosuppressive drugs in the blood is a common diagnostic 
method to determine mainly drug toxicity and patient compliance. (Kowalski et aI., 2003) 
An assessment was made of the levels of cyclosporine, sirolimus and tacrolimus 
measured in whole blood obtained from patients' medical records according to the A TP 
bioluminescence assay results of the patients in the respective immunosuppressant drug 
groups. (Refer to figure 3.17, 3.18, 3.19) 
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No correlation was observed between patients' A TP (ng/ml) results and therapeutic drug 
levels measured in the cyclosporine (r2=0.0146), sirolimus and tacrolimus groups 
r=0.2825 and r=0.0017 respectively. This highlights the importance of measuring the 
cumulative effect of the drugs on immune system. 
This lack of correlation may be attributed to differences in each individuals' 
pharmacokinetic responses. Each patient immune system responds differently to immune 
suppressant regimens based on their age, ethnicity, presence of medical conditions such 
as diabetes, osteoporosis, cardiovascular disease and the strength of the patients immune 
system. (Danovitch, 1999., Ojo et aI., 2000) 
The method used for determining the therapeutic drug level targets one drug and does not 
take into account the effect of other drugs administered e.g. steroids, antiproliferatives or 
antimetabolites. (Jusko and Thomas, 1995., Yatscoffet aI. , 1990) A study by Israeli M. et 
aI. , 2007 found A TP based assay to have a higher level of correlation with patient clinical 
status than calcineurin inhibitor blood levels (CNI). (Israeli et aI., 2007) 
In accordance with previous studies, regression analysis indicated no correlation was 
observed between A TP production of lymphocytes from transplant recipients and 
immunosuppressive drug dosages (Figure 3.20, 3.21 , 3.22), creatinine levels (Figure 
3.23) and white cell counts (WCC) (Figure 3.24) (Chavez et aI. , 2006). 
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The lack of an association between the drug dosages, creatinine levels and WCC may be 
as a result of the difference in each patients' pharmacokinetic response to the 
immunosuppressive drugs, (Kowalski et aI. , 2003) also factors that effect immune 
response such as stress and inflammation in the graft may not be reflected in creatinine 
levels or WCC. Creatinine is a late indicator of rejection it is elevated after cellular 
infiltration has taken place therefore it is a poor indicator of complications within the 
graft. WCC fails to measure the viability of the cells; a high count does not correlate with 
increased A TP production as the test does not take into account whether the cells are 
functionally compromised. (Johnston and DW, 1999., Kowalski et aI., 2006) 
In order, to interpret the A TP results a standard range of values is required to compare the 
results to and characterise the individuals' immune response as low, moderate or strong. 
For this study the immune cell response of healthy controls and patients on cyclosporine, 
sirolimus and tacrolimus were characterised according to these three different ranges that 
were arbitrarily chosen based on the mixture of ATP results observed <200 nglml was 
considered a low immune response, 201-500 nglml a moderate immune response and 
>501 nglml a strong immune response. Future studies are required to establish a more 
precise range to our setting/laboratory by testing the assay on a larger population of 
known healthy and immunocommpromised individuals. 
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In figure 3.25 the immune cell response of patients on cyclosporine, sirolimus and 
tacrolimus were characterised according to the three different ranges and were plotted 
against the time since transplantation. The ATP bioluminescence assay results do not 
directly quantify the level of immune suppression therefore the results are described in 
conjunction with clinical presentation (Kowalski et aI., 2003) to give a complete picture 
of the patients' immune status. 
Within the past five years approximately 30 new transplantations were carried out at the 
IALCH thus the number of patients in the, one year group were far and few between. 
Majority of the patients who have had a transplant for more than one year, appeared to 
have a moderate or low immune response, possibly indicating that the effectiveness of the 
immunosuppressive therapy on the immune system improves over time despite the 
patients being on lower doses of the drugs/maintenance therapy. (Kowalski et aI., 2003) 
Over time the continuous consumption of immunosuppressant drugs results in reduced 
immune response to the newly transplanted organ but the immune system becomes 
suppressed to such an extent that it leads to an increase in incidences of infection , 
malignancies, drug toxicities etc. (Zeevi et aI., 2005., Dantal et aI., 1998) 
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In the cyclosporine group no patient gave a strong immune response over the three time 
periods. The vast majority (n=14), were in the moderate immune response range. Three 
of the patients who had an immune response characterised as moderate presented with 
urinary tract infection (UTI) and one with suspected bronchopneumonia at the time of the 
test, the rest were considered to be clinically stable. 
Five (40%) of the twelve patients who received their kidney transplant within 1-10 years 
and three (30%) of the ten patients who received a transplant more than 10 years ago had 
a low immune response «225 ng/ml). Seven of these patients with a low immune 
response were considered clinically stable at the time of the test only one patient was 
diagnosed with UTI. 
Within the sirolimus group four (50%) of the eight patient's in the 1-10 years 
transplantation group had a low immune response «225 ng/mI). Three of these patient's 
were clinically stable and one presented with CMV infection and recurrent UTI. 
The patient who gave a strong immune response (>525 ng/mI) in the 1-10 years 
transplantation group was considered to be clinically stable. The remaining three were in 
the moderate immune response range; one of these patients displayed symptoms of UTI 
and suspected TB and the other two patients were considered clinically stable. 
94 
One patient in the Tacrolimus group was newly transplanted and displayed a strong 
immune response with an ATP (ng/ml) level of 667 ng/ml, his clinical status showed 
raised wee, urea and creatinine levels. A biopsy that was carried out did not point to 
acute rejection however acute rejection was suspected based on his clinical picture. He 
had no symptoms of infection. 
Of the remaining five patients on tacrolimus in the 1-10 year time period, one was tested 
to have a strong immune response and two each with a moderate and low immune 
response. The patient with the strong immune response showed no signs of rejection 
however he was treated for dermatological related conditions. Of the two patients with 
the low immune response, one was clinically stable and the other presented with recurrent 
Klebsiella UTI and the patients in the moderate range were clinically stable. 
Table 3.6 represents the results of the transplant patients in all three drug groups that 
were pooled and classified according to their clinical status (rejection, infection and 
stability) and the immune response standard range. Patients diagnosed with an infection 
were more frequent in the moderate (n=5) and low (n=3) immune response range. Of the 
patients diagnosed as clinically stable twelve patients (n=12) were included in the low 
immune response zone and fifteen patients (n=15) in the moderate immune response 
range. 
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Infection was confirmed via microbiological culture. The mean A TP levels for patients 
with infection was 248 nglml ATP (±SEM40.52, n=8) and those that were stable 
257 nglml A TP (±SEM28.82, n=29). No statistically significant difference was measured 
between the means. 
It has been reported by Gautam et aI., (2006) that a single determination of the A TP level 
has limited diagnostic value, serial determination using the patients as his or her own 
control provides more information of patients at risk of infection or rejection. (Gautam et 
aI., 2006) 
Figure 3.26 depicts the immune response distribution of five patients who were tested 
monthly for three months. All five patients maintained an immune response status within 
the low and moderate immune response range over the time period. (refer to appendix 15) 
Patient one and patient four maintained a moderate immune response over the three 
months. Patient one had no signs of infection or rejection over the three months his 
medical history indicated, he had gingival enlargement (cyc1osporine toxicity) and 
recurrent haematuria. Patient four clinical indicators also shows no sign of rejection 
however had a recent history of septic wound post removal of a Tenckhoff dialysis 
catheter removal from the abdomen however healing was good. 
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Patient two and three displayed moderate to low immune response, patient two was 
diagnosed with a UTI and patient three presented with a cough, night sweats and sinusitis 
and a rapid loss of weight bronchopneumonia was suspected during the test period. 
Patients 5 results over the three months ranged between moderate and low, the clinical 
history showed no indicators for rejection however diagnosis of influenza, UTI and 
infection of the upper gum was made. 
The results of some patients interchanged between low and moderate immune response 
A TP range between each month, with no distinct changes in the clinical status, possibly 
since the patients were rejection free the A TP levels did not change dramatically 
therefore further studies is required in a larger cohort of patients preferably in pre and 
post transplantation when the risk of rejection is higher (Kowalski et aI., 2006) to 
accurately determine the predictive value of the assay. 
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The response of PBMC' s to the stimulant PHA in the presence of plasma isolated from 
patient's blood and plasma from healthy individual's was also investigated. (Refer to 
table 3.8 and table 3.9) We found that the level of ATP (ng/ml) measured in the presence 
of patient's plasma in both the control and immunosuppressant drug groups were lower 
than the levels of A TP (ng/ml) measured without plasma. It was also found that plasma 
isolated from healthy individuals incubated with PBMC's from the control group as well 
as from patients in the immunosuppressant drug groups resulted in the lowest level of 
A TP (ng/ml) measured. 
In the control group, PBMC's incubated with plasma from patients on either 
cyc1osporine, tacrolimus or sirolimus a mean of774 ng/mllevel of ATP (30.5% increase) 
was measured as compared to 1247 ng/ml ATP (47.69% increase) in the absence of 
plasma from patients. Surprisingly in the presence of plasma from the healthy controls a 
lower level of 325 ng/ml A TP ( 13.67% increase) was measured. 
In the cyc1osporine group when patients' PBMC's were incubated with their plasma, a 
mean of 48 ng/ml ATP (3.4% increase) was measured as compared to 227 ng/ml ATP 
(11.4% increase) in the absence of plasma. Surprisingly in the presence of plasma from 
the healthy control there was no increase in ATP (-547 ng/ml ATP; -31.4% decrease), 
proliferation was inhibited. 
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In the sirolimus group when patient PBMC's were incubated in the presence of their 
plasma, a mean of 86 nglml level of A TP (4.1 % increase) was measured as compared to 
255 nglml A TP (11.99% increase) in the absence of plasma. Surprisingly in the presence 
of plasma from the healthy controls there was no increase in A TP (-416 nglml ATP; -
21.2% decrease), proliferation was inhibited. 
In the tacrolimus group when patient PBMC's were incubated with their plasma, no 
increase in ATP was measured (-176 nglml ATP; -6.2% decrease) as compared to 366 
nglml ATP measured (21.62% increase) in the absence of plasma from patients. In the 
presence of plasma from the healthy control there was also no increase in A TP 
(-1072 nglml A TP; -83.1 % decrease), proliferation was inhibited. 
It appears that plasma isolated from patients on immunosuppressant drugs and more so 
plasma from healthy controls contains factors which suppress the response of 
lymphocytes to PHA stimulation. The concept that plasma proteins are capable of 
inhibiting immune response was first demonstrated by Kamrin et.al., (1959) Plasma 
lipoproteins carry out lipid transport and bioregulatory roles. (Hui et aI., 1980) 
Suppression of lymphocyte proliferation by human plasma lipoproteins has been 
observed in a variety of studies. (Curtiss and Edgington, 1980) Alpha-globulin-enriched 
fractions from human plasma have been shown to possess immunosuppressive properties. 
(Mowbry, 1963) 
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A study by Cooperband et aI., (1972) reported that a globulin fraction of plasma may 
play a role in the regulation of the immune response. It is able to suppress immune 
responses in vivo and prevents lymphocyte proliferation in vitro. The study demonstrated 
that a globulin is elevated when patients are undergoing renal rejection and a globulins 
isolated from these patients suppress PHA induced lymphocyte stimulation in vitro. It is 
assumed that the mechanism by which a globulin functions to prevent stimulation of 
lymphocytes may be by noncompetitive inhibition of activation. This implies that there is 
a receptor for the a globulin and another for the mitogenic stimulus. The mitogen 
receptor will not carry out its metabolic events when the a globulin receptor is activated. 
(Cooperband et aI., 1972) 
Inhibition of lymphocyte stimulation by PHA has been observed with plasma lipoproteins 
that regulate several aspects of lymphocyte function and metabolism. All the classes of 
lipoprotein fractions; Very Low Density Lipoproteins, Intermediate Density Lipoproteins, 
Low Density Lipoproteins, and High Density Lipoproteins were shown to inhibit the 
mitogen-induced stimulation of lymphocyte proliferation in a study by Morse et aI., 
(1977) (Morse et aI., 1977., Cuthbert and Lipsky, 1983., Hui et aI., 1980) 
Plasma lipoproteins, particularly those containing apolipoproteins Band E, have been 
shown to suppress mitogen activation and subsequent proliferation of peripheral blood T 
lymphocytes.(McCarthy et aI., 1987) 
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Hence a possible explanation for the suppressed immune response and decreased A TP 
levels measured in the presence of plasma from healthy controls may be as a result of 
lipoproteins in the plasma. Future studies are required to confirm this as well as optimise 
the ATP bioluminescence assay to include plasma in the assay. 
The suppressed response to plasma from patients may be attributed to the fact that plasma 
plays a role in the distribution of the drug in the body. The drugs may occur in plasma as 
free and unbound or bound to plasma proteins. Hence when incubated with the PBMC's 
the presence of the immunosuppressant drugs in the plasma results in a further 
suppression. (Wasan, K.M, 998) 
Hyperlipidemic plasma has also been shown to have an inhibitory effect on lymphocyte 
proliferative responses to mitogenic stimulation in culture in several clinical conditions 
including nephrotic syndrome. (Lenarsky et aI., 1982., Martini et aI., 1981) 
Hyperlipedemia is a known side effect of cyclosporine, tacrolimus as well as 
sirolimus.(Sayegh et aI., 1999) 
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The assay under investigation is similar to an FDA approved assay known as 
ImmunKnowTM immune cell function assay manufactured by Cylex lnc@, (Columbia, 
MD, USA) which briefly involves overnight incubation of whole blood with PHA, after 
which CD4 cells are selected using paramagnetic particles coated with a monoclonal 
antibody to the CD4 epitope followed by lysis of the cell and A TP measurement. 
(Kowalski et aI., 2003) 
The protocol of the assay evaluated in this research study differs from the ImmunKnow™ 
immune cell function assay in that it does not involve the use of whole blood or 
separation of CD4 T cell. 
Studies by Barten et aI., (2002) and Copeland et aI. , (1988) stated that using whole blood 
when stimulating the cells with PHA allows the lymphocytes to be maintained in the 
presence of the immunosuppressive drugs which are partitioned between the red cells 
membrane (Barten et aI., 2002., Copeland and Yatscoff, 1988) in conjunction Zeevi et aI. , 
(1996) reported that a prolonged incubation time of 5-7 days with out red blood cells 
results in lymphocytes recovering from suppression and hence an increase in the recall 
responses and alloreactivity of T cells. (Zeevi and Duquesnoy, 1996., Kowalski et aI. , 
2003) 
However, in view of the fact that the assay under investigation requires only an overnight 
incubation of PBMC's with PHA in the absence of red blood cells, the concern of the 
lymphocytes reverting to their original strength is negligible. 
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The protocol of the assay under evaluation did not involve the isolation of CD4 T 
lymphocytes but rather makes use of peripheral blood mononuclear cells (PBMC's) i.e. a 
mixture of lymphocytes and monocytes. It has been stated by the Cylex Inc research 
group that CD4 T cells were isolated as they playa major role in rejection. (Kowalski et 
aI., 2003) 
Purified peripheral blood mononuclear cells were utilised based on the view that using 
the mixture of cells has more clinical relevance, allowing the lymphocytes to be 
maintained in an environment comparable to which the cells interact in vivo. 
CD4 T cells do not work in isolation; they play an immunoregulatory role via cytokines 
(IL2) therefore suppression of CD4 T cells results in overall suppression of the cells it 
interacts with. By removing a specific subset of T cells from a mixed population of cells 
results in the accessory cells which are required for the response of T cells to antigens not 
to be present. PHA is not sufficient to fully activate CD4 T cells to proliferate it requires 
co-stimulation by other immune cells such as monocytes. (Grimm, 2006., Halvorsen et 
aI., 1988., McCarthy et aI., 1987) 
Magnetic separation of specific immune cells as in the ImmunKnow™ immune cell 
function assay is expensive and requires special equipment. Separation of lymphocytes 
by magnetic affmity techniques may result in changes in the lymphocytes which may 
affect further tests on the isolated cells. The separation of a subset of lymphocytes from 
whole blood requires a further wash step to remove cells that are bound non-specifically. 
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It is also difficult to preserve the sterility of the sample once the cells are removed from 
the original environment. (Wier, 2007) 
Transplant recipients are on a variety of immunosuppressant drugs which inhibit a range 
of immune cells. While cyclosporine and tacrolimus specifically target T lymphocytes, 
sirolimus on the other hand has a non specific antiproliferative effect it targets the cell 
cycle which includes all dividing cells and azathioprine and mycophenolate mofetil 
which prevents the expansion of both T cells and B cells. (Sayegh et aI., 1999) Hence it 
was decided to not limit the study by isolating CD4 T cells. 
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Potential drawbacks of the study: repeated cultures using the lymphocytes of one 
individual showed variation in the A TP levels calculated after stimulation. It must be 
noted that many factors other than pharmacologic immune suppression may influence 
PBMC's and specifically T cell function, results may vary as T cells are affected by the 
time of day the blood sample is taken (circadian/diurnal variation), fatigue and stress. 
(promega, 2005., Grimm, 2006) Good reproducible results are dependent on appropriate 
handling of reagents, cell counts and plating techniques. Bioluminescence reagents are 
sensitive to extremes in temperature and bright light. 
All material of cellular origin will give a response with an ATP bioluminescence method, 
i.e. somatic/non microbial and microbial cells all contain ATP. ATP is fairly heat stable, 
autoclaving may not be sufficient therefore in order to prevent contamination necessary 
precautions need to be taken. (Redsven et aI., 2007) 
To ensure a uniform number of cells, cells were counted using a hemacytometer, this 
technique has substantial accuracy error due to its' subjective nature and it may result in 
an over estimation or under estimation of the number of viable cells, it is also laborious 
allowing only a few tests to be performed simultaneously. However the advantages of 
counting cells using a hemacytometer is that it is a cost effective method to distinguish 
viable cells using light microscopy and only a small fraction of cells are required. (Trauth 
and Keesey, 1996) 
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The ATP bioluminescence assay requires fresh blood. The blood sample needs to be used 
within 30 hours to ensure good proliferation of cells following mitogen stimulation. The 
use of fresh blood, however, is a potential drawback as it does not allow the processing of 
a large number of samples in a short period of time and collection of fresh blood samples 
over a long period of time may be affected by seasonal and experimental variations. The 
use of cryopreserved cells allows better planning of a study, replication of experiments to 
confirm results, and the option of repeating a test if there are inaccuracies. It will also 
allow retrospective investigations on the predictivity of ATP of the status of the immune 
system by using the blood sample obtained before the first clinical signs of a 
complication occurred. (Zijno et aI., 2007) 
A paper by Bohler T et aI., 2007 which looked at biomarkers for pharmocodynamic 
monitoring of immunosuppressive drugs questions the role of ATP as a efficacy 
biomarker, since A TP reflects the overall energy metabolism of cells it is not specific in 
determining the effects of immunosuppressive drugs. The pharmocodynamic monitoring 
biomarkers considered to be more specific and investigated in the study were intracellular 
cytokine expression (IL2 and TNFu) which respond to immune suppressants in a more 
specific way. (Bohler et aI., 2007) Future research may involve the evaluation of the 
immunomodulatory effects of currently used immunosuppressive regimens on peripheral 




The assay described in this study is part of the growing interest and research in the 
development of quick, convenient and reliable assays to monitor the immune system. The 
immunological markers currently under investigation include serum CD30, specific anti 
donor antibodies, interferon gamma enzyme linked immunosorbent assay (ELISA), 
perforin granzyme B in urine and proteomic techniques. (Israeli et a!., 2007., Rodrigo et 
a!., 2008) The ultimate aim is to improve on currently available diagnostic tests which 
will allow for early and non invasive detection and prevention of complications as well as 
improve on strategies to obtain the optimal immunosuppressive dose. 
The proposed bioluminescence method for the evaluation of the proliferative response of 
T lymphocytes by measuring ATP production was shown to be sensitive and simple in 
keeping with previous work by research groups namely Cree and Andreotti, 1997., 
White et a!., 1989., Crouch et a!., 1993., Ishizaka et a!., 1984. The assay is non 
radioactive, it is a simple straight forward protocol and employs standard equipment and 
standard cell culture formats. The results obtained with the A TP bioluminescence assay 
evaluated in this study further validated A TP as a marker for monitoring lymphocyte 
function. 
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The kidney transplant patients on immunosuppressive drugs gave a significantly lower 
immune response than controls. Clinical findings of high frequency of various infections 
in the patient population support the overall findings. However determining the 
correlation between the immune response invitro and invivo requires a larger population. 
The predictive value of the A TP bioluminescence assay investigated in this study was 
insufficient for directing immunosuppressive therapy. 
The future challenges include developing the assay further by performing follow up 
studies to improve the method and to validate the role of the assay in managing immune 
suppression in a larger patient population. The A TP bioluminescence assay has potential 
to be used in the assessment of the immune response in other scenarios e.g. the effect of 
debilitating infectious diseases like mY/Aids on the immune system and monitoring 
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Components of blood following centrifugation 
Blood is composed of erythrocytes or red blood cells, platelets and leukocytes. When 
blood is removed from the circulatory system and centrifuged it separates into different 
layers because of the different densities of the cells. Plasma forms the yellow translucent 
supernatant, erythrocytes make up the lower layer in the centrifugation tube and the white 
or grayish layer immediately above the separation medium is made up of the peripheral 
blood mononuclear cells (PBMC's) which consists of lymphocytes and monocytes. 





Fig 7.27: Schematic representation of blood following centrifugation 
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Leukocytes/ White blood cells (WBC) 
Leukocytes play an important role in the bodys' defense against foreign agents. Each type 
of leukocyte has specialised functions and their roles varies between specific and non 
specific immune defense. There are five types of leukocytes present in circulation which 
are divided into two groups. Granulocytes, which include neutrophils, basophils and 
eosinophils. Agranulocytes or mononuclear cells which include lymphocytes and 
monocytes. The concentration of leukocytes in the blood changes according to gender, 
age and physiologic conditions. In normal adults there are approximately 10 000 
leukocytes per microliter of blood. (Junqueira et al., 1995) 
Lymphocytes 
Lymphocytes are characterised by a round densely stained nucleus and small amount of 
pale basophilic non granular cytoplasm. In blood 80% of the lymphocytes are T 
lymphocytes, a far smaller percentage of circulating lymphocytes are represented by B 
lymphocytes. The life span of T lymphocytes last for several months or years while B 
lymphocytes survive for about 10-20 days. T lymphocytes like B lymphocytes do not 
produce antibodies but rather bind to foreign antigens. (Junqueira et al., 1995) 
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Immunosuppressant drugs classification and dosage 
Table 7.10: Immunosuppressant drugs classification and dosage (*- dosage depends on 
the medical condition being treated, severity of the condition and presence of other 
medical conditions, age, weight) (Halilovic and Kenna, 2006) 
Generic name Brand name Dosa(!e* 
Cyclosporine, Cy A Neoral® + 5 mglkg/day 
Rapamycin, Sirolimus Sirolimus® + 8 mg/day 
Tacrolimus, Fk506 Prograf@ + 0.2 mg/kg/day 
Prednisone - + 5-60 mg/day 
Mycophenolate mofetil CellCept® + 1000 mg/twice day 
Azathioprine Imuran® + 1-3 mg/kg 
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Red blood cell lysis 
Sterile distilled water was used to remove any contaminating red blood cells (RBC's) and 
platelets. A few drops of distilled water was added and resuspended with the cell pellet 
after about 10 seconds, approximately lOml of PBS was added. The RBC's swell when 
placed in distilled water, because of osmosis and eventually burst. 
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Preparation of PHA 
The PHA lyophilised powder was reconstituted with PBS according to manufactures 
instruction and further diluted as follows. 
100111 of the original 1 mg/ml solution was added to 9900Jll PBS to make a 1: 100 dilution, 
thus, giving a final concentration of 1 Jlg/ml. The solution was aliquoted into labeled 1ml 
eppendorff tubes and stored at -20oe. 
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Table 7.11: Questionnaire 
Hospital Number KZ-
Date Information is 
taken 
Translator 




Participant Medical History 









Blood levels of 
immunosuppressive 













Normal range for white cell count and creatinine levels 
Table 7.12: Normal range for white cell count and creatinine levels (Drovan and Krentz, 
2002) 
Investigation Normal Ran~e 
White cell count 4.0-11.0 x 10 9 II 




Blood donation guidelines 
• Weight >50kg 
• Age: 17 - 65 
• Good Health 





Information document for participants 
Greetings, my name is Saleha Omarjee, I am a medical science masters student and I plan 
on doing research on kidney transplant patients. Research is just the process to learn the 
answer to a question. In this study I want to learn more about the immune response in 
kidney transplant patients. 
The title of my study is Assessment of the Immune Response in kidney Transplant 
Patients 
I am inviting you to take part in my research study. 
Your role in this study would be to give a blood sample during your routine visit to the 
IALCH renal transplant clinic 
Risks of being involved in the study are minimal as a blood sample which is routinely 
taken, will be drawn from you. 
Your participation in this study is voluntary. If you refuse to participate, you will not be 
penalised. Please note that you may stop participation at any time without penalty. 
Great care will be taken to ensure that all your personal information remains confidential 
although absolute confidentiality cannot be guaranteed. Personal information may be 
disclosed if required by law. 
Contact details for further information: 
Miss Saleha Omarjee email:201292883@ukzn.ac.za, tel:031-260 4225 
Supervisor: Prof A. Assounga email: assoungaa@ukzn.ac.za, tel: 031-2604217 
Contact details of BREC Administrator or Chair - for reporting of complaints/ problems: 
Biomedical Research Ethics, Research Office, UKZN, Private Bag X54001, Durban 4000 
Telephone: +27 (0) 31 2604769/260 1074 
Fax: +27 (0)312602384 
Administrator: Ms P Ngwenya email: ngwenyap@ukzn.ac.za 
Chair: Email: ProfD R Wassenaar email: c/ongwenyap@ukzn.ac.za 
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Information document for control 
Greetings, I, Saleha Omarjee a medical science masters student, intends on doing 
research on kidney transplant patients. Research is just the process to learn the answer to 
a question. In this study we want to assess the immune system of kidney transplant 
patients. 
Study title: Assessment of the Immune Response in kidney Transplant Patients 
I am inviting you to kindly participate in this research study as a control. The definition 
of a control is "A standard against which other conditions can be compared in a scientific 
experiment" . 
The inclusion criteria, to be a control is an apparently healthy male or female adult who is 
eligible to donate blood according to the established blood donation guidelines. 
If you have consented to be a control a blood sample will be taken and utilised in my 
study as a comparison to the blood samples of kidney transplant patients who are on 
various immunosuppressant therapies attending the Inkosi Albert Luthuli Renal unit. 
Risks: of being involved in this study is minimal. 
Benefits: By donating a blood sample you will be assisting in increasing scientific 
knowledge and improving the quality of life of kidney transplant recipients. 
Great care will be taken to ensure that all your personal information remains Confidential 
although absolute confidentiality cannot be guaranteed. Personal information may be 
disclosed if required by law. 
Your participation in this study is voluntary. If you refuse to participate, you will not be 
penalised. Please note that you may stop participation at any time without penalty. 
Contact details of Researcher: Miss Saleha Omarjee, email:201292883@ukzn.ac.za. 
tel:031-260 4225 
Supervisor: Prof A. Assounga, email:assoungaa@ukzn.ac.za 
Contact details of BREC Administrator or Chair - for reporting of complaints/ problems: 
Biomedical Research Ethics, Research Office, UKZN, Private Bag X54001, Durban 4000 
Telephone: +27 (0) 31 2604769/260 1074 
Fax: +27 (0) 31 2602384 
Administrator: Ms P Ngwenya email: ngwenyap@ukzn.ac.za 
Chair: Email: ProfD R Wassenaar email: c/ongwenyap@ukzn.ac.za 
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Consent to Participate in Research 
You have been asked to participate in a research study 
You have been informed about the study by Prof AGH. Assounga and Saleha Omarjee 
You may contact Saleha Omarjee at 031-260-4225 during office hours if you have 
questions about the research or if you are injured as a result of the research. 
You may contact the Medical Research Office at the Nelson R Mandela School of 
Medicine at 031-2604604 if you have questions about your rights as a research subject. 
Your participation in this research is voluntary, and you will not be penalised or lose 
benefits if you refuse to participate or decide to stop. 
If you agree to participate, you will be given a signed copy ofthis document and the 
participant information sheet which is a written summary of the research. 
The research study including the above information, has been described to me orally. I 
understand what my involvement in the study means and I voluntarily agree to 
participate. 
Signature of Participant 
Signature of Witness 
(Where applicable) 







Imvume yokubamba Igbaza ocwaningweni 
Uceliwe ukuthi ubambe iqhaza ocwaningweni 
Uchazeliwe ngalolu cwaningo ngu Prof. AGH. Assounga and Saleha Omatjee 
Lapho kufanele: uchazeliwe ngezinxephezelo ezingase ezikhona noma ukwelashwa uma 
kwenzeka uthola ukulimala ngenxa yalolucwaningo. 
Ungaxhumana no Saleha Omarjee kule nombolo : 031 260 4225 ngazozonke izikhathi 
uma uma unemibuzo eqondene nalolu cwaningo. 
Ungathintana nehhovisi lezocwaningo (I medical research office) elise Nelson R. 
Mandela Medical School kulenamba: 031 260 4604 uma unemibuzo eqondene 
namalungelo akho njengo muntu obambe iqhaza kulolu cwaningo. 
A wuphoqelekile ukuthi ubambe iqhaza kulolu cwaningo kungokuthanda kwakho, futhi 
ungeke uhlawuliswe noma ulahlekelwe uma ungabami iqhaza noma unquma ukuhoxa 
kulolu cwaningo. 
Vma uvuma ukusebenzisana nathi, uzonikwa ikhophi esayiniwe yalolu cwaningo( 
yaledocuument) kanye nepheshana elinolwazi oluthize lwababame iqhaza. Lokhu kuzobe 
kune ncazelo efmqiwe noma emfushane ngalolucwaningo. 
Ngichazeliwe ngomlomo ngenhloso yalolucwaningo kanye nalolwazi olongenhla. 
Ngiyakuqonda okufanele ngikwenze kulolucwaningo futhi ngiyavuma ngokuthanda 











Table 7.13: Results obtained for each individual included in the cyclosporine group 
percentage clinical status 
Drugs wee 
date of ATP blood creatinine Group gender race increase (before-during-after levels 
x 109/1 
l.lInoVI transplant nglml 
ofATP the test Age nglml 
1 
Cyclosporine Male Indian 




2 Cyclosporine Male 44 Indian 1998 115 3.69% stable 523 7.25 102 
3 
Cyclosporine Male African 
stable, warty lesion 809 4.68 105 
48 2001 144 3.71% on abdomen 
4 Cyclosporine Male 54 Indian 2002 260 9.41% stable, septic wound 1125 3.72 261 
5 Cyclosporine Male 66 Indian 1992 286 15.86% stable 1229 10.3 152 
6 
Cyclosporine Male White 
recurrent UTI, 927 7.76 118 
45 1999 131 13.07% papules on the face 
7 Cyclosporine Male 58 Indian 1993 349 36.09% stable 911 6.32 112 
8 Cyclosporine Male 39 White 2000 283 14.13% stable 648 6.8 112 
9 Cyclosporine Male 55 Indian 1998 150 5.94% stable 506 11.34 108 
10 Cyclosporine Male 54 Indian 1991 30 2.68% stable 771 12.97 143 
11 Cyclosporine Female 56 Indian 1999 306 7.67% stable, UTI 871 7.19 166 
12 Cyclosporine Female 45 Indian 1993 265 8.65% Gastritis 1390 6.4 112 
13 Cyclosporine Female 27 White 2001 342 12.64% bronchopneumonia 814 7.55 148 
14 Cyclosporine Female 53 Indian 1997 397 14.99% UTI, gum infection 786 6.82 163 
15 Cyclosporine Female 40 Coloured 1998 84 2.95% stable 819 5.57 122 
16 Cyclosporine Female 45 White 1991 206 9.23% stable 512 8.18 127 
17 Cyclosporine Female 41 Coloured 1989 261 11.18% UTI 953 8.1 155 
18 Cyclosporine Female 68 Indian 1996 13 0.51% stable 798 8.99 85 
19 Cyclosporine Female 57 Indian 1996 330 17.53% stable 625 6.15 89 
20 Cyclosporine Female 47 Indian 2005 323 18.58% neurotoxicity, angina 784 6.5 112 
21 Cyclosporine Female 43 African 1999 383 11.46% stable 651 4.24 85 
22 Cyclosporine Female 67 Indian 1993 197 9.31% stable 756 8.78 100 
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Table 7.14: Results obtained for each individual included in the sirolimus group 
Percentage drug blood 
wee 
Date of ATP clinical status x creatinine Group gender age Race 
transplant (nglml) 
Increase 
(before-during-after the test) 
level 109/1 /lIDO III 
ofATP (nglml) 
1 Sirolimus Male 24 Indian 2004 564 21.08% stable 14.2 8.37 126 
2 Sirolimus Male 23 Indian 1999 126 3.91% stable 6.7 7.96 425 
3 Sirolimus Male 36 Indian 1995 266 8.34% stable 10.9 6.24 146 
4 Sirolimus Male 19 African 2003 350 19.81% stable 15.1 3.98 107 
5 Sirolimus Male 61 Indian 1988 291 16.84% stable 7.7 5.01 201 
6 
Sirolimus Female 50 African 2001 UTI, recurrent cough, inc 6.5 
7.74 185 
327 11.27% weight loss 
7 Sirolimus Female 64 African 1998 246 14.83% stable, gum hypertrophy 3.2 10.19 109 
8 Sirolimus Female 37 Indian 2002 121 8.43% CMV infection, UTI 6.6 7.77 103 
9 Sirolimus Female 23 Indian 2005 134 4.91% stable 7.9 8.76 102 




Table 7.15: Results obtained for each individual included in the tacrolimus group 
Percentage drug blood 
wee I 
Date of ATP clinical status x creatinine Group gender age race 
transplant (nglml) 
Increase (before-during-after the level 109/1 /lmolll 
ofATP test) (nglml) 
1 
Tacrolimus male 15 Indian 1998 102 4.85% stable, recurrent UTI 6.1 5.04 129 
2 
Tacrolimus male 38 Indian 2007 stable, papules on the 7.4 
6.53 140 
677 19.01% face 
3 Tacrolimus male 16 Indian 2008 667 74.03% stable 7.2 11 90 
4 Tacrolimus male 21 White 2005 250 17.08% stable 12.7 11.3 160 
5 stable, 9.4 4.45 158 
Tacrolimus Female 35 black 1999 422 hypopigmentation face 
11.04% and thorax 
6 Tacrolimus Female 35 Indian 1998 78 3.72% stable 7.1 6.47 74 
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Table 7.16: Results obtained for each of the five patients from the cyclosporine group tested over a three month period 
(Pred: predisinone" Aza: azatheropine Mmf: mycophenolate mofetil) 
Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 
Cyclosporine 50mg 75mg 225mg 75mg 25mg 
dosage (mg) 
Other drug Pred 5mg Mmf1000mg Mmf750mg Pred 7.5mg Pred 2.5mg 
dosage Aza 75m! Pred 5mg Aza 50mg Mmf1000mg 
Drug Blood 842 1055 427 871 - 337 814 221 662 1125 797 606 786 639 383 
levels ng/ml 
Creatinine 133 124 97 - 166 219 148 105 146 261 216 211 163 128 173 
Ilmol/l 
WCC x 109/1 7.85 8.12 8.66 7.19 6.32 6.61 7.55 9.08 6.91 3.72 4.51 4.95 6.82 5.51 6.66 
Clinical haematuria, gum UTI Suspected Septic wound UTI-gum 
status hypertrophy Bronchopneumonia infection 
ATP level 497 294 225 306 50 213 342 104 187 260 264 312 397 119 402 
Percentage 18% 15% 10% 7% 4% 11% 11% 3% 7% 9% 19% 12% 13% 3% 11% 
increase of 
ATP 
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